# PROTOCOL

#### for the

# DIABETES PREVENTION PROGRAM OUTCOMES STUDY

# (DPPOS)

IND # 49,782 ClinicalTrials.gov # NCT00038727

Diabetes Prevention Program Outcomes Study Research Group

Date: March 1, 2014

# Version 3.4

Version 1.0 May 30, 2002 Version 1.1 October 8, 2002 Version 2.0 November 18, 2004 Version 2.1 July 5, 2006 Version 3.0 February 2, 2009 Version 3.1 April 20, 2011 Version 3.2 June 25, 2012 Version 3.3 February 11, 2013

Distributed by the DPPOS Coordinating Center Located at The Biostatistics Center The George Washington University 6110 Executive Boulevard, Suite 750 Rockville, Maryland 20852

# **Table of Contents**

1. EXEC	CUTIVE SUMMARY	4
1.1.	Background	4
1.2.	Objectives	5
1.3.	Study Population	6
1.4.	Study Interventions	6
1.5.	Outcomes (see Chapter 4)	6
1.6.	Design and Power.	8
1.7.	Analyses	8
2. OBJE	CTIVES	9
2.1	Primary Pasaarah Question	0
2.1.	Secondary Research Questions	وو ۵
2.2.	Other Research Questions	ر و
3 BACK	CROUND AND PATIONALE	)
J. DACI		10
3.1.	The Diabetes Prevention Program	10
3.1.1.	Study Rationale and Design	10
3.1.2.	Study Cohort	11
3.1.3.	Outcome Data from DPP	12
3.1.4.	Study Results	13
3.1.5.	Bridge Period Between End of Masked Intervention and Initiation of DPPOS	15
3.2.	Rationale for Extended Follow-up of DPP Cohort in DPPOS	16
3.2.1.	Duration of Diabetes Prevention	16
3.2.2.	Long-term Impact of DPP Interventions on Composite Outcomes Including Microvascul	ar
and Cardiovas	cular Disease	16
3.2.3.	Summary	18
3.3.	Clinical Course of IGT and New-onset Type 2 Diabetes	19
3.3.1.	Epidemiology of Microvascular Disease and Neuropathy in IGT and New-onset Type 2	
Diabetes	$\frac{19}{1000}$	21
3.3.2.	Epidemiology of CVD in IGI and New-onset Type 2 Diabetes	21
3.3.3.	Summary	23
3.4. 2.4.1	Bick Exercise for True 2 Disk day and Disk day and to d Counciliantian in Minarity	23
5.4.1.	Risk Factors for Type 2 Diabetes and Diabetes-related Complications in Minority	
Populations	24	
4. DEFI	NITION OF OUTCOMES	26
4.1.	Primary	26
4.1.1.	Glycemia: OGTT and FPG (primary during Phase 1 and secondary during Phase 2)	26
4.1.2.	Composite Diabetes-related Microangiopathic and Neuropathic Primary Outcome	27
4.1.3.	Composite Diabetes-related Cardiovascular Disease Secondary Outcome	27
4.2.	Other Secondary Outcomes	27
4.2.1.	Glycemia and insulin secretion:	28
4.2.2.	Cardiovascular disease and risks, assessed by:	28
4.2.3.	Retinopathy, assessed by:	28
4.2.4.	Nephropathy, assessed by:	28
4.2.5.	Neuropathy, assessed by:	28
4.2.6.	Physical activity, nutrition, behavioral, and body mass and obesity, assessed by:	29
4.2.7.	Health related quality of life, assessed by:	29
4.2.8.	Resource Utilization, Costs, Health Utilities, and Effectiveness of treatments, assessed b	y:29
4.2.9.	Safety tests:	29
4.2.10	. Serologic evidence of type 1 diabetes, assessed by:	29
4.2.11	Stored specimens:	29
4.2.12	Other chemistries:	30

4.	2.13. Other research outcomes:	
5. S'	FUDY DESIGN	31
- 1		
5.1.	Overall Design	
5.2.	Participation Criteria	
5.3.	Principles Guiding the Selection of a Study-wide Group Lifestyle Intervention	
5.4.	1 iming and Condition of Outcomes Assessment	
5	4.1. Development of Diabetes	
).	4.2. Other Outcomes	
5.5.	Masking	
6. P.	ARTICIPANT MANAGEMENT PROTOCOLS	34
6.1.	Schedule of Follow-up Visits	
6.	1.1. Interim Visits	
6.	1.2. Confirmation (CON) Visits	
6.	1.3. Suspension of Follow-up Visits	
6.	1.4. Home or Telephone Visits	
6.2.	Lifestyle Program in DPPOS Years 1-12	35
6.	2.1. Lifestyle Resource Core and Lifestyle Advisory Group	
6.	2.2. Staff for Lifestyle Interventions	
6.	2.3. HELP Program	
6.	2.4. Boost Lifestyle (BLS)	37
6.	2.5. Indices of Adherence	37
6.3.	Metformin Pharmacological Treatment	
6.	3.1. Description of Intervention	38
6.	3.2. Mechanism of Metformin Action	38
6.	3.3. Dosing Schedule and Restarts	39
6.	3.4. Safety Monitoring and Measures to Reduce and Manage Potentially Drug relate	d side
Effects	39 25 J.V. CALL	12
0.	5.5. Indices of Adherence	
7. D	EFINITION AND MANAGEMENT OF CONCOMITANT CONDITIONS	43
7.1.	Hypertension	43
7.	1.1. Goals of Therapy	
7.	1.2. Outcome Assessment	
7.2.	Hyperlipidemia	43
7.	2.1. Diabetic Participants	43
7.	2.2. Non-diabetic Participants	44
7.3.	Cardiovascular Disease	44
7.	3.1. Myocardial Infarction or Unstable Angina	44
7.	3.2. New Angina Pectoris	44
7.	3.3. PTCA or Coronary By-Pass (CABG)	44
7.	3.4. Medical Treatment	45
7.4.	Psychological Diseases and Use of Psychoactive Agents	45
7.5.	Pregnancy and Contraception	45
7.	5.1. Safety Monitoring	45
7.	5.2. Use of Study Interventions During Pregnancy and Breast-feeding	45
7.	5.3. Outcomes Assessment Following Pregnancy	46
7.6.	Smoking	47
7.7.	Type 2 Diabetes	47
7.	7.1. Interim Visits for Symptoms	47
7.	7.2. Intervention and Follow-up for Participants with Diabetes	47
7.8.	Retention Monitoring and Recovery of Inactive Participants	48
7.9.	Determining Vital Status and Cause of Death for Participants	48
8. A	DVERSE EVENT REPORTING	49

8	8.1.	Definitions	49
8	8.2.	Eliciting and Recording Serious Adverse Events	49
9.	DAT	A PROCESSING	50
Ç	9.1.	Data Forms	50
	9.1.1	Other Forms	51
Ģ	9.2.	Data Entry and Management System	52
	9.2.1	Clinical Centers	52
	9.2.2	. Central Biochemistry Laboratory	52
Ģ	9.3.	Centralized Data Management System	52
9	9.4.	Performance Monitoring	53
	9.4.1	. Training Workshop and Site Visits	53
(	9.5.	Interim Statistical Reports	54
10.	STU	DY ADMINISTRATION	55
	10.1.	Organizational Units	55
	10.1.	1. Clinical Centers	55
	10.1.	2. Coordinating Center	55
	10.2.	Funding Mechanism/Study Resources	55
	10.3.	Working Committees	56
	10.3.	1. Steering Committee and Subcommittees	56
	10.3.	2. Data Safety Monitoring Board	56
	10.4.	Policies	57
	10.4.	1. Publications	57
	10.4.	2. Ancillary Studies	57
11.	STA	FISTICAL CONSIDERATIONS	59
	11.1.	Data Relevant to the Primary Outcome	59
	11.2.	Study Power	
	11.3.	Analysis	60
	11.3.	1. Analysis of Development of Diabetes	60
	11.3.	2. Composite Outcomes of Microangiopathic, Neuropathic and Cardiovascular Disease	61
	11.3.	3. Secondary Research Questions	61
-	11.4.	Monitoring	62
12.	OUT	COMES SCHEDULE	63
	12.1.	Visit Schedule	70
13.	STU	DY TIMETABLE	71
14.	BIBI	JOGRAPHY	72

#### 1. EXECUTIVE SUMMARY

#### 1.1.Background

Type 2 diabetes mellitus (Ty2DM) is rapidly becoming the most common chronic disease in the United States, with more than 8% of the adult population affected and 1,900,000 new cases per year. Ty2DM is even more common in the elderly and in minority populations including African Americans, Hispanic Americans, Asian and Pacific Island Americans, and Native Americans. In these populations, Ty2DM may be present in 10% to as much as 50% of the adult population. Diabetes is accompanied by a multitude of severe long-term complications that ultimately cause more adult cases of blindness, renal failure, and amputations than any other disease in the United States. In addition, persons with Ty2DM have a 2 to 4 fold increased risk for cardiovascular and peripheral vascular disease and stroke. Owing largely to the high costs of caring for Ty2DM and its attendant long-term complications, total health care costs for diabetes have been estimated at approximately 176 billion dollars per year, or 12% of total U.S. health care expenditures. The enormous human and financial costs that accompany Ty2DM, and the difficulty in treating it effectively once it has developed, make it an appropriate target for prevention.

The Diabetes Prevention Program (DPP) was a multicenter controlled clinical trial examining the efficacy of an intensive lifestyle intervention or metformin to prevent or delay the development of diabetes in a population selected to be at high risk due to the presence of impaired glucose tolerance (IGT). Development of diabetes, defined by 1997 ADA criteria, was the primary outcome while cardiovascular disease and its risk factors were important secondary outcomes. The DPP began recruitment in mid-1996 and completed recruitment approximately three years later with a study cohort composed of 68% women, 45% minorities, and 20%  $\geq$  age 60. All 3,234 volunteers received standard lifestyle recommendations and were randomly assigned to one of three interventions: intensive lifestyle with the aim of losing and maintaining 7% weight loss and achieving  $\geq$  150 minutes per week of moderate intensity physical activity, metformin therapy with 850 mg twice per day, or placebo. The troglitazone intervention in a fourth treatment arm (n=585) was discontinued in June 1998 because of the potential risk for severe liver toxicity that became apparent after the DPP was initiated.

The DPP had excellent retention, with >99% of the study cohort alive at study end and 93% of annual visits completed. In addition, the intensive lifestyle cohort achieved a mean weight loss of 7% (14.5 lb.) and 224 minutes per week of physical activity by the end of the 16-session core curriculum (at approximately 6 months) and maintained a 5% weight loss (10.3 lb.) and 189 minutes of activity per week after a mean study duration of 2.8 years. Seventy-two percent of participants assigned to metformin and 80% of those assigned to placebo took at least 80% of assigned medications during the study.

On the basis of a statistically significant and clinically compelling decrease in the development of diabetes in the lifestyle intervention and metformin-treated groups (58% and 31% reduction in hazards, respectively) compared with the placebo treated group, the DPP Data Monitoring Board and NIDDK ended the masked treatment phase of the study in August, 2001, one year earlier than originally planned.

At the end of the DPP all participants were offered a lifestyle modification program that incorporated the features of the original intensive lifestyle intervention, but was implemented in group sessions during a 4-6 month period. The participants originally assigned to metformin

continued open-label metformin therapy, and those assigned to placebo-treatment stopped the placebo.

The DPP addressed its primary objective, establishing the efficacy of lifestyle modification and metformin in decreasing the incidence of diabetes in an ethnically diverse population at high risk for an average of 2.8 years; however, many important issues remain unanswered. Specifically, whether the decrease in the development of diabetes can be sustained is unknown. Moreover, determining whether the delay or prevention of diabetes will translate into a decrease in retinopathy, nephropathy, neuropathy, and cardiovascular disease, all of which require more years to develop than the DPP period of study, is critical to establish the true impact of the DPP on public health.

The long-term follow-up study of the DPP, entitled the Diabetes Prevention Program Outcomes Study or DPPOS, was designed to take further advantage of the scientifically and clinically valuable cohort of DPP volunteers and the large volume of data collected during the study to address the issues above. The highly compliant DPP cohort, including 45% minorities, is the largest IGT population ever studied. Moreover, the large number of new onset type 2 diabetic patients, carefully followed from near the time of their true onset, provides an unparalleled opportunity to study the clinical course of type 2 diabetes.

More than 87% of the original surviving DPP cohort joined DPPOS as of December, 2007 and after 5 years of DPPOS and 10 years of combined DPP/DPPOS, 93% of the DPPOS cohort continued to attend annual follow-up visits. Interim analyses performed after 5 years of DPPOS demonstrated a durable effect of diabetes prevention associated with the lifestyle and metformin interventions with 34 and 19% reductions in diabetes incidence, respectively, compared with the placebo group. Interim analyses also revealed significant reductions from baseline in CVD risk factors in the lifestyle intervention group, but with decreased utilization of glucose-lowering and lipid-lowering medications. Analyses of the participants in the placebo group who have developed diabetes during DPP/DPPOS, compared with those who have remained non-diabetic, reveal an increased frequency of retinopathy and microalbuminuria. The previous protocol version (3.3) described the DPPOS including the revisions incorporated to complete the second phase of DPPOS.

The DPPOS is approved to collect data through study year 12, which ends for participants between June and October 2014. DPPOS was granted an extra year of funding to continue participant visits while we analyze outcomes to determine whether further follow-up is merited and, if so, to prepare a new funding application. Continuation of study visits is considered important to maintain continuity and retention of the cohort while the continuation application is prepared and evaluated. Since protocol version 3.3 only covers participant visits through study year 12 (ending October 2014), version 3.4 adds DPPOS study year 13 visits, which will commence on July 1, 2014. The visits during this period will include, for the purposes of continuity, similar content as previous DPPOS visits, except as specifically noted, mirroring the anticipated measurement structure of the planned continuation study.

#### 1.2.Objectives

The primary objective of the DPPOS is to evaluate the long-term effects of active DPP interventions on the further development of diabetes (during the first phase of DPPOS), and on macrovascular composite events and composite diabetes-related microvascular complications. During the second phase of DPPOS, the hypothesis being tested is that, compared to the former

placebo group, both the continued lifestyle intervention and metformin groups will experience a reduced rate of microvascular and neuropathic complications.

The secondary objectives of the DPPOS are to evaluate the long-term effects of DPP interventions on the further development of diabetes and selected individual health outcomes, the established and putative risk factors for those outcomes, and the costs and cost-utility associated with delay or prevention of diabetes.

Other research objectives include examining and comparing the incidence and determinants of these health outcomes in participants with new-onset diabetes and IGT, as well as assessing subgroups of participants in order to evaluate the effect of race/ethnicity, age, and gender on health outcomes.

# **1.3.Study Population**

All DPP participants, assigned to the original intensive lifestyle, metformin, troglitazone, and placebo groups, whether or not they developed diabetes during the DPP, were eligible and were invited to join DPPOS. The former troglitazone participants were followed during Phase 1 of DPPOS, but no longer participate as research volunteers in the study. At the time that DPPOS was initiated in September 2002, the mean age of the study population (including the former troglitazone participants) was 55 years, with 68% being women. Fifty-five percent were Caucasian, 20% African-American, 16% Hispanic American, 4% Asian or Pacific Islander-American, and 5% American Indian. A total of 2776 out of the original 3234 DPP participants consented to participate in DPPOS (86.8% of surviving participants). Among intensive lifestyle, metformin, and placebo participants who joined DPPOS, 770 DPPOS participants had been diagnosed as having diabetes as of September, 2002, and another 503 participants developed diabetes during the first phase of DPPOS. As of January, 2014, an additional 277 DPPOS participants have developed diabetes, for a total of 1550 DPPOS participants (56%) having developed diabetes.

# **1.4.Study Interventions**

During DPPOS, quarterly group meetings will be held for all participants through summer 2014. These will focus on lifestyle lectures as well as other topics of interest to participants with IGT or diabetes. Additional group lifestyle boost sessions will be offered to the group originally assigned to intensive lifestyle intervention through spring 2014 and open label metformin therapy (850 mg twice per day) will continue to be provided to the participants originally assigned to metformin.

# **1.5.Outcomes (see Chapter 4)**

<u>Microvascular and neuropathic</u>: The primary outcome for Phase 2 of DPPOS is the presence of one or more of the following at the year 11 visit, or if the participant is deceased or lost to follow-up before Year 11, the presence of one or more of the following as of his/her last assessment:

a. Nephropathy: micro- or macro-albuminuria (≥30 mg/gram creatinine, confirmed), or renal dysfunction (end-stage renal disease, dialysis or renal transplant) or GFR < 45

ml per min based on serum creatinine, using the CKD-EPI equation or another validated algorithm; the qualifying criteria confirmed)

- b. Retinopathy: retinopathy by fundus photography (ETDRS grade of 20 or greater) or adjudicated history of laser or other treatment for retinopathy or
- c. Neuropathy: reduction or absence of light touch sensation to monofilament (Semmes-Weinstein 10 gram) in either foot (< 8 of 10 applications detected).

If a participant is taking antihypertensive drugs at the last assessment and does not meet the ACR or eGFR criteria at that time, he or she may be considered to have reached the nephropathy outcome if the nephropathy criteria were met at 2 consecutive past visits. This may substitute for the occurrence of nephropathy at Year 11.

# The secondary outcomes include:

- Further development of diabetes (defined below)
- Diabetic retinopathy
- Diabetic neuropathy
- Albuminuria
- Renal failure
- Macrovascular disease (defined below)
- Cardiovascular disease events
- Subclinical atherosclerosis outcomes
- Risk factors for cardiovascular disease
- Amputation in a lower extremity not resulting from major trauma
- Hospitalizations
- Physical activity, nutrition, body mass and obesity
- Dietary and exercise behaviors
- Physical functioning
- Quality of life indices
- Health care costs
- Cognitive performance
- Urinary incontinence
- Cancer incidence

The *diabetes* outcome is the same as the primary outcome during the DPP, i.e. development of diabetes according to American Diabetes Association criteria (fasting plasma glucose level  $\geq$  126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose  $\geq$  200 mg/dL [11.1 mmol/L], after a 75 gram OGTT, and confirmed with a repeat test).

The DPPOS *macrovascular* outcome is the time to first occurrence of any one or more of the individual events as listed below:

- a. cardiovascular disease (CVD) events (CVD death, fatal and non-fatal myocardial infarction and stroke)
- b. silent myocardial infarction on EKG
- c. coronary artery stenosis  $\geq$  50% documented by angiography
- d. coronary revascularization

- e. hospitalized CHF
- f. hospitalized unstable angina/acute coronary syndrome
- g. revascularization or amputation in lower extremity not resulting from major trauma

CVD events are determined at the time of their report and classified and adjudicated by an outcomes committee whose members are blinded to treatment assignment.

#### 1.6. Design and Power

All active participants have been followed during DPPOS for a minimum of eleven years, with a total mean follow-up of approximately 15 years from the beginning of DPP. Two additional years of followup (DPPOS Years 12 and 13) were added to allow retention of participants and continued assessment of clinical outcomes pending analysis of the primary outcome, and to prepare new funding applications.

The power analysis at entry to DPPOS was as follows: Based on the high rate of adherence during DPP and enrollment in DPPOS, we estimate that 85% of all participants will elect to continue in DPPOS. The global test will provide 91% power for detecting a 25% reduction in microvascular complications due to intervention, from a projected placebo group average prevalence of 12.1% (each of 2 pair-wise comparisons, 2-sided,  $\alpha$ =0.025), and 74% power for a 20% reduction (1). These estimates pertain to the DPPOS Year 11 analyses that are currently underway; final results are not yet available.

#### 1.7. Analyses

The primary outcome analysis will compare the three intervention groups with respect to the DPPOS year 11 assessment of the components of the microangiopathy outcome using the global test (1). The global test, which gives the component outcomes equal weight, is interpreted as testing for a consistent difference between groups across the component outcomes. The primary and secondary outcome analyses will follow the "intention to treat" principle and will include all participants in the original DPP placebo, lifestyle and metformin intervention groups who have enrolled in DPPOS. Since the participants originally assigned to troglitazone only had a limited exposure to that intervention, owing to the premature termination of the troglitazone arm, and were not included in the primary DPP outcome analyses, they will not be included in the DPPOS primary and secondary outcome analyses.

# 2. OBJECTIVES

# **2.1.Primary Research Question**

The primary objective of the DPPOS is to evaluate the long-term effects of the DPP interventions (Intensive Lifestyle and Metformin, currently Boost Lifestyle, and Metformin) on the prevalence of the composite diabetes-related microangiopathic and neuropathic outcome.

## **2.2.Secondary Research Questions**

The secondary objective of the DPPOS is to evaluate the long-term effects of DPP interventions on selected health outcomes including:

- Further development of diabetes
- Diabetic retinopathy
- Diabetic neuropathy
- Albuminuria
- Renal Failure
- Macrovascular disease
- Cardiovascular disease events
- Subclinical atherosclerosis outcomes
- Risk factors for cardiovascular disease
- Amputation in a lower extremity not resulting from major trauma
- Hospitalizations
- Physical activity, nutrition, body mass and obesity
- Dietary and exercise behaviors
- Physical functioning
- Quality of life indices
- Health care costs
- Cognitive performance
- Urinary incontinence
- Cancer incidence

The outcomes chosen as secondary objectives were selected based on their clinical importance, demonstrated association with diabetes, and the possibility that they would be responsive to the DPP interventions.

#### **2.3.Other Research Questions**

Other research questions of the DPPOS include examining and comparing the incidence and determinants of these health outcomes in participants with new-onset diabetes and IGT, as well as assessing subgroups of participants in order to evaluate the effect of age, race/ethnicity, and gender on health outcomes.

#### 3. BACKGROUND AND RATIONALE

#### **3.1.The Diabetes Prevention Program**

#### 3.1.1. Study Rationale and Design

The Diabetes Prevention Program (DPP) was a multicenter controlled clinical trial examining the efficacy of an intensive lifestyle intervention or metformin vs. placebo to prevent or delay the development of diabetes in a population selected to be at high risk due to the presence of impaired glucose tolerance (IGT) (2-4). Development of diabetes, defined by 1997 ADA criteria (5), was the primary outcome while cardiovascular disease (CVD) and its risk factors were important secondary outcomes. The original study design included four treatment arms: intensive lifestyle (ILS) intervention, troglitazone (TRO) treatment (400 mg/day), metformin (MET) treatment (850 mg twice per day), or placebo (PLB). All medication-treated subjects received identical appearing coded medications, and treatment was double blind. Troglitazone treatment was stopped in June 1998, owing to the accumulating evidence that troglitazone was responsible for rare, but potentially severe idiosyncratic liver toxicity. The volunteers assigned to troglitazone therapy were offered a modified lifestyle intervention and continue to be followed as a separate group in the DPP.

The original rationale for a study to prevent or delay diabetes was the following: 1. Diabetes mellitus, and in particular Type 2 diabetes (Ty2DM), had become epidemic in the US, affecting 8% of the adult population and with almost 1,900,000 new cases per year (6); 2. The consequences of Ty2DM including diabetes-specific complications, such as retinopathy, nephropathy, and neuropathy, and cardiovascular disease were causing severe morbidity and mortality with enormous human and financial costs (7); 3. Although therapies to treat diabetes once it develops were available, the complex medical regimens required were difficult and costly to apply and many patients failed to achieve the glycemic levels and other treatment goals required to prevent or delay the long-term complications; 4. A pre-diabetic state was well recognized, and could be identified with relatively simple screening methods, providing the opportunity of identifying persons at high risk for diabetes (8); and, finally, 5. Potentially modifiable environmental factors, such as overweight and a sedentary lifestyle, that were known to increase risk for diabetes (9-11), and medications that ameliorate hyperglycemia had been identified. In concert, these factors suggested that interventions with the potential to prevent or delay the development of diabetes could be applied in persons identified at high risk to develop diabetes mellitus, a common chronic disease with grave long-term consequences.

The DPP was designed with the expectation that prevention or delay of diabetes would ultimately prevent or delay the development of long-term, duration dependent diabetes-specific complications. In addition, prevention or amelioration of CVD and/or CVD risk factors would provide a major benefit to those with IGT or diabetes. Accomplishing either of these aims would provide a major benefit with regard to long-term health by virtue of decreasing morbidity and mortality. However, the duration of the DPP, planned as a 3-6 year study, did not allow an examination of whether "prevention" or delay of diabetes would translate into a reduction of clinical outcomes that usually require a longer period of time to develop. Thus, the DPP was designed on the basis of power calculations directed at diabetes prevention (2). The ability to demonstrate a reduction in microvascular complications or "hard" CVD endpoints was acknowledged from the outset to be limited. Instead, changes in CVD risk factors and measures of atherosclerosis, such as ankle/brachial index and carotid ultrasonography, were analyzed.

### 3.1.2. Study Cohort

The DPP recruited its study cohort between June 1996 and 1999, screening more than 150,000 self-referred individuals. Oral glucose tolerance testing (75 grams) was performed in approximately 20,000 persons to select high-risk individuals with impaired glucose tolerance (IGT) with two-hour plasma glucose values 140-199 mg/dL. The eligibility criteria also required a fasting glucose level of 95-125 mg/dL, representing approximately the upper half of the IGT population. Based on previous epidemiological studies (8), this population was projected to have a conversion rate to diabetes of 7.5% per year. (2,8) The baseline characteristics of the study population have been described in detail. (3) (Table 1)

At the time of the analysis of study end data (visits completed as of April 1, 2001), total study exposure was a mean of 2.8 years (range 1.8 to 4.6) with a total of  $\approx$ 10,000 patient years in the 3,234 volunteers in the 3-arm study. (See Table 1 for Baseline Characteristics of DPP Cohort, 3) An additional  $\approx$ 2,000 years of follow-up data had been collected in the approximately 550 volunteers in the ex-troglitazone treated group. Finally, 623 members of the DPP cohort developed diabetes during the course of the study, with the expectation that more will develop diabetes over time. (8) The date of diabetes onset is known within 6 months of its actual occurrence, due to repeat glucose testing throughout the trial.

	Overall	Lifestyle	Metformin	Placebo
Ν	3234	1079	1073	1082
Age (yr)	51±11	51±11	51±10	51±10
Sex:				
Male	1043(32%)	345(32%)	363(34%)	335(31%)
Female	2191(68%)	734(68%)	710(66%)	747(69%)
Race/ethnicity:				
Caucasian	1768(55%)	580(54%)	602(56%)	586(54%)
African-	645(20%)	204(19%)	221(21%)	221(20%)
American				
Hispanic	508(16%)	178(17%)	162(15%)	168(16%)
American-	171(5%)	60 (6%)	52 (5%)	59 (6%)
Indian				
Asian-	42(4%)	57 (5%)	36 (3%)	49 (5%)
American				
Fasting	5.9±.5	5.9±.5	5.9±.5	5.9±.5
glucose				
(mmo1/L)				
BMI (kg/m <sup>2</sup> )	34±7	34±7	34±7	34±7
Blood pressure				
(mmHg)				
Systolic	124±15	124±15	124±15	124±14
Diastolic	78±9	79±9	78±10	78±9

#### **Table 1: Baseline Characteristics of DPP Cohort**

From Diabetes Care 2000; 23:1619-29 (3)

Data are means + SD or n(%) unless otherwise stated. Percentages may not add up to 100 because of rounding.

The DPP population represents the largest cohort of IGT subjects, including a large representation from minority populations in the US, followed over time. (Table 1)

#### 3.1.3. Outcome Data from DPP

Study data included: measurements of glycemia, including mid-year or annual fasting and OGTT glucose values and HbA1c levels; measurements of insulin and proinsulin (to help determine underlying causes of decline in glucose tolerance and as putative risk factors for CVD); demographic and clinical variables that reflect risk for diabetes and/or CVD such as body mass index, weight distribution, direct measures of fat mass/distribution (CT scans on a sample), blood pressure, lipids; biochemical measures that are established or putative risk factors for the development of CVD including hemorheological factors; clinical CVD events categorized and adjudicated in a similar fashion to other interventional and epidemiological studies; and measures of atherosclerosis such as ankle/brachial index measured by Doppler and carotid intimal-medial thickness (IMT) measured by B-mode ultrasonography. Finally, the DPP has stored samples that are suitable for analysis of other putative risk factors or mediators of diabetes or CVD that could not be afforded during the study. Samples suitable for genetic analysis have also been collected, and are being analyzed. In addition, samples have been kept in storage for participants who consented. All data collected include standardized measurements using uniform methods and central analysis/reading/grading with easily accessible stored data.



# **Time to diabetes**



# 3.1.4. Study Results

After approximately 2.8 years of mean study time, the external Data Monitoring Board and sponsoring institute, the NIDDK, concluded that the DPP had convincingly demonstrated that the intensive lifestyle intervention and metformin therapy decreased the development of diabetes. Compared with placebo, intensive lifestyle and metformin reduced the development of diabetes by 58% and 31% risk reduction, respectively. (Fig 1) Both results were significant and lifestyle was significantly more effective than metformin. (4) The therapies were effective across all ethnic and racial groups and in men and women. The intensive lifestyle intervention cohort achieved the target goal of 7% mean weight loss and at least 150 min of activity per week at year 1. (Table 2) The entire cohort proved to be remarkably compliant, with 94% retention of volunteers over time, and completion of  $\geq$  90% of study requirements. Adherence (>80% of assigned medication) to metformin was 72%.

	Placebo	Metformin	Lifestyle
Development of diabetes (percent per year)	11	7.8	4.8
Reduction of diabetes compared with placebo (%)		31	58
Number needed to treat to prevent 1 case in 3 y		13.9	6.9
Weight loss kg (%)			
Year 1	.43(0.5)	2.72(2.9)	6.7(7.2)
Year 2	.06(0.1)	2.07(2.2)	5.4(5.7)
Year 3	37(-0.4)	1.18(1.3)	4.7(5.0)
Leisure Activity (Met hours /wk)			
1 year	4.46	4.92	5.57
2 year	4.61	4.37	5.27
3 year	4.95	4.29	5.08

# **Table 2: Summary of Outcomes During DPP**



Figure 2 Summary of DPP and DPPOS Timeline

# 3.1.5. Bridge Period Between End of Masked Intervention and Initiation of DPPOS

A summary of important dates in DPP history and the DPPOS follow-up is shown in Figure 2.

The DPP Research Group decided before the study results were known, to offer effective therapy to the cohort at study end, should one of the study interventions prove to be effective. This decision was made not from any scientific imperative, but based on the sense of the DPP Research Group and NIDDK that initiating effective therapy was consistent with our obligation to the participants who had made the DPP possible. During the final six months of the DPP (January – June 2002), under a "bridge" protocol, all participants were offered an intensive Lifestyle program with the same goals used in the DPP, but offered in a group, rather than individual, setting. In addition, during this period, the former ILS group was offered continued ILS, albeit with a less frequent contact than during the DPP. Placebo therapy was stopped after

individual unmasking took place between August and November 2001. MET was continued, during this period, with participants and staff unmasked to treatment assignment.

#### 3.2. Rationale for Extended Follow-up of DPP Cohort in DPPOS

The DPP was designed to ascertain whether metformin treatment and/or intensive lifestyle modification reduced the development of diabetes, compared to placebo, in subjects with IGT during a period of intervention averaging  $\cong$ 4 years. (2) Owing to the large and statistically significant reduction in development of diabetes in the lifestyle intervention group (58%) and in the metformin-treated group (31%), compared with placebo treatment, the DPP was ended, by consensus of the external Data Monitoring Board, NIDDK, and the Study Group, approximately one year earlier than planned. (Figure 2) The prevention – or delay - of diabetes should be associated over time with a reduced rate of diabetes-related clinical events, namely diabetic microangiopathy and neuropathy and cardiovascular disease (CVD). The relatively brief study period of the DPP, with a mean follow-up of 2.8 years (range 1.8-4.8 years), precluded an examination of the long-term clinical impact of diabetes prevention. An appreciation of the long-term clinical impact of diabetes prevention is critical in order to understand the role of the DPP interventions in improving health. Moreover, the long-term epidemiological follow-up of the DPP cohort will increase our understanding of the clinical course of IGT and new-onset type 2 diabetes.

#### 3.2.1. Duration of Diabetes Prevention

The major question that arises is whether the therapies that were effective during the DPP continue to prevent diabetes and how long the effect persists. Long-term follow-up of the DPP cohort will reveal whether the differences in diabetes development decrease, remain the same or increase over time. The duration of the effect of DPP interventions on the development of diabetes has an obvious impact on the interpretation of the study's effect, given the life-long risk for developing diabetes, and the duration-dependent impact of diabetes on health. Other controlled clinical trials such as DASH (9), examining the impact of a lifestyle intervention with salt restriction on hypertension, the EDIC follow-up of the DCCT (10), and the long-term follow-up of the United Kingdom Prospective Diabetes Study (UKPDS) cohort (12) have demonstrated persistent, or even expanded, benefits of initial therapy over time. Such long-term follow-up studies are critical to understand the effects of therapy on chronic conditions.

# **3.2.2.** Long-term Impact of DPP Interventions on Composite Outcomes Including Microvascular and Cardiovascular Disease

#### 3.2.2.1 Microvascular and Neuropathic Disease

The second question addresses the long-term clinical impact of having prevented or delayed the onset of diabetes. As noted above, the ultimate health care benefit of diabetes "prevention" will be a function of the time period during which diabetes is delayed, and whether and to what extent organ damage can be prevented or delayed. Although epidemiological data suggest that prevention or delay of diabetes should result in less disease over time, no study has ever addressed this critical public health question directly.

The development of diabetic retinopathy, nephropathy and neuropathy is believed to require chronic exposure to levels of glycemia at or above the diagnostic limits for diabetes (5). Thus, based on conventional thinking, the appearance of these complications in DPP participants would be expected to be restricted to those who develop diabetes, and would be expected to occur only some years after biochemical conversion. The decreased development of diabetes with intensive lifestyle and metformin would, therefore, be expected to reduce the frequency and extent of these disease entities compared with their occurrence in the former placebo-treated group. Although an assessment of the development of microvascular complications during the DPP was discussed during the planning stages, it was not implemented, because of the added expense and the likelihood that event rates would not be high enough within the planned DPP duration to enable group differences to be detected. However, a difference between treatment groups in these duration-dependent outcomes, if one exists, is more likely to be demonstrated with longer follow-up. The ultimate benefit of preventing diabetes is predicated, to a large extent, on the projected decrease in the development of long-term complications. Follow-up of the DPP cohort during DPPOS will determine whether this effect has been achieved.

#### 3.2.2.2 Cardiovascular Disease (CVD)

Whether CVD, the complication associated with greatest morbidity and mortality in diabetes (10), was altered by DPP therapies was examined during the DPP, albeit with limited power owing to a low event rate. Previous studies have demonstrated that diabetic subjects have higher rates of CVD than individuals with IGT, who in turn have higher rates than persons with normal glucose tolerance (NGT). (13,14) Therefore, prevention or delay in development of diabetes and/or reversion to NGT from IGT, both of which occurred in the DPP, could influence the course of CVD in a significant proportion of DPP participants. In addition, both metformin and lifestyle modification have been shown to improve CVD risk factors directly. (15-19) Metformin has modest beneficial effects on the lipid profile, and lowers PAI-1 levels. (15,16) In obese diabetic subjects, metformin treatment may reduce the incidence of myocardial infarction by mechanisms that may be at least partly independent of blood glucose lowering. (17) Weight reduction and increased physical activity also improve the lipid profile, lower blood pressure and increase fibrinolytic activity. (18,19) Increased physical activity has been associated with a reduced incidence of CVD in non-diabetic and diabetic subjects. (20-22)

Unfortunately, the DPP had insufficient power to detect an effect of the two active DPP interventions on CVD events owing to the relatively low rate of CVD events during the study (0.0029 major clinical CVD events per year). However, the effect of interventions on several subclinical markers of CVD (ankle/brachial index and silent ECG changes) and on CVD risk factors was examined. Although the low event rates of major CVD precluded demonstrating a difference in event rates between the treatment groups, CVD risk factors were variably affected by the different DPP interventions. (Table 3) Blood pressure was significantly lower, lipid levels were less atherogenic, and insulin levels were lower in the Lifestyle treatment group, and to a lesser extent with metformin therapy, than in the placebo group. Longer follow-up of the DPP cohort will be highly informative regarding the effects of therapy on clinical outcomes that are likely to take longer to observe than the initial 3 years of the DPP.

<b>CVD Risk Factors</b>	Placebo	Metformin	Lifestyle
Blood pressure (mmHg)			
Systolic	-0.77	-1.12	-3.26
Diastolic	-0.74	-0.86	-3.27
Lipoproteins (mg/dL)			
Total cholesterol	-3.26	-4.72	-8.14
Triglycerides	-3.39	-3.04	-21.98
LDL-cholesterol	-1.37	-4.00	-4.37
HDL-cholesterol	27	0.39	0.69
Insulin level (µU/ml)			
Fasting	0.74	-2.93	-4.52
30 min Post-OGTT	1.45	-6.92	-13.49

#### Table 3: CVD Risk Factors during DPP-Mean Change from Baseline

### **3.2.2.3 Economic Implications**

The economic impact of the DPP treatments will be a function of any significant differences in health outcomes over time. There is evidence that diabetic subjects experience higher health care costs than do non-diabetic subjects. (23) Analysis of the cost-effectiveness of the DPP interventions has demonstrated a cost per quality adjusted life year that is within the range usually considered affordable.(24) These analyses have not considered the potential long-term effects of the DPP on complications. In order to understand the true costs and benefits of DPP interventions, we must delineate the long-term clinical outcomes associated with the interventions. Reduced long-term health care costs associated with the DPP interventions that delay diabetes and, presumably, diabetes-associated complications, would offset the costs of the interventions and therefore favorably affect the cost-effectiveness and cost-utility ratios.

#### 3.2.3. Summary

In view of these issues, an examination of the putative reduction in diabetes complications and health care costs that may result from the DPP interventions is the requisite next step in providing the clinical evidence that medical intervention in subjects with IGT yields important and tangible health benefits. The DPPOS will analyze the health care outcomes discussed above on the basis of the intention-to-treat groups in DPP. This approach has been used to good effect in several completed clinical trials; e.g. the DCCT (EDIC) (10), the Coronary Drug Project (25,26) and 4S (27). Long-term follow-up of controlled clinical trials involving chronic diseases is predicated on the notion that the study intervention influences certain chronic disease processes in a manner that takes more time to manifest than the duration of the treatment being studied. One of the best examples of such a study was the Coronary Drug Project, in which coronary and all-cause mortality were not altered at the completion of a 6-year period of niacin therapy even though cholesterol levels were significantly lowered. (25) However, these clinical endpoints were significantly reduced after 9 years of further observational follow-up. (26) The ongoing EDIC follow-up of the DCCT cohort has demonstrated widening differences in

The Biostatistics Center, George Washington University Rockville, Maryland outcomes as early as 4 years after the termination of assigned therapies. In addition, longer follow-up has demonstrated differences in more advanced and costly complications, including the need for laser therapy for proliferative retinopathy atherosclerosis and CVD events, between the treatment groups that were not apparent at the end of the DCCT. (10,10a) Lastly, evaluation of the United Kingdom Prospective Diabetes Study cohort 10 years following completion of the intervention phase of the study has demonstrated significant differences in a number of outcomes in subjects previously randomized to the intensive and conventional treatment arms. Thus, despite glucose control not differing between the subjects following completion of the intervention, in those who had received the intensive glucose-lowering regimen, continued significant reductions in risk were observed in any diabetes-related endpoint and microvascular complications and a significant reduction in risk became apparent for myocardial infarction and all-cause mortality. (11)

#### 3.3.Clinical Course of IGT and New-onset Type 2 Diabetes

## **3.3.1.** Epidemiology of Microvascular Disease and Neuropathy in IGT and Newonset Type 2 Diabetes

The "specific" long-term complications of diabetes mellitus have been used to establish the glycemic thresholds at which diabetes occurs. Therefore, the nosologic definition and diagnostic criteria for diabetes mellitus are based on elevated glycemia and the risk for development of retinopathy. (5) The 1997 report by the Expert Committee of the American Diabetes Association was based on a relatively small number of observational, cross-sectional studies that established a threshold below which retinopathy was generally not detected. (5) Other cross-sectional studies also suffer from inaccurate assessment of diabetes onset (41,42), and only a few have been performed in minority populations (43-45), leaving our understanding of the frequency and clinical course of retinopathy incomplete. Longitudinal studies, such as WESDR and studies in the Pima Indians, also suffer from inadequate dating of diabetes onset. In the study in the Pima Indians, the diagnosis of diabetes onset could not be more accurate than within 4 years. (45) Of interest, retinopathy was present in 11.2% of 169 subjects "at the time of diagnosis" and in 12% of persons with IGT. The suggestion in the high diabetes-prevalence population of Pima Indians of a greater risk for "diabetes-specific" complications in nondiabetics than previously appreciated may or may not be relevant in other populations. While duration of diabetes is a well-known risk factor for retinopathy, and other complications, in most populations, when the "clock starts ticking" is unknown. Finally, only a small number of studies (45-47) have examined the prevalence of retinopathy in IGT populations. They have been limited in being generally cross-sectional with poor appreciation of the glycemic history of the participants. Of note, the results of a pilot study during DPP/DPPOS, in which we have excellent measures of glycemia over time, have shown a prevalence of diabetic retinopathy of 7.9% in participants who had not developed diabetes compared with 12.6% prevalence in the sample of DPP participants who had developed diabetes with a mean duration of 3.1 years during DPP. (47a)

Epidemiologic (48,49) and interventional studies, such as the Diabetes Control and Complications Trial (50) and the United Kingdom Prospective Diabetes Study (51) have contributed to our understanding of the relationship between glycemia and complications by performing secondary analyses that plot the development (or risk for progression) of retinopathy against mean hemoglobin A1c over time. These studies have had to extrapolate to the nondiabetic range; there were too few patients with "normal" hemoglobin A1c results to provide reliable estimates of risk in the low diabetic or high normal levels of hemoglobin A1c.

Despite the sometimes fierce ideological battles regarding the correct threshold at which diabetes can be diagnosed, the data on which such decisions have been made have not included patients studied from time of true onset. Moreover, all of the epidemiological studies to establish glycemic thresholds for the diagnosis of diabetes have relied on retinopathy as the complication that is most easily measured quantitatively and objectively. There are relatively few studies that examine the occurrence of kidney dysfunction, and specifically microalbuminuria, early in the course of diabetes, although it is known that microalbuminuria occurs in IGT and in the normal glucose tolerant (NGT) population, where it appears to impart increased risk for CVD events and mortality. (52,64) A few studies show that increased albumin precedes the onset of Ty2DM. (52) There is very little hard data on microalbuminuria (MA) prevalence rates in IGT. A study in Nauruans (55) found it to be ~60% higher than in NGTs (absolute prevalence of 43%) and newly diagnosed diabetic subjects had a ~2.5 fold increased prevalence. The Finnish data (52) are probably more representative at 11.0%. The rates in most studies of clinically newly diagnosed diabetic subjects indicate a prevalence of 10-30%; in 2 studies the prevalence was at least 5-6 times higher than that in a control population (52,54,55,59,60,61). The incidence tends to progress with duration, but it is not a clear linear progression (53,56,57). In one study the prevalence almost doubled over 10 years from the value at the time of diagnosis (53). Since an important relationship exists with insulin resistance (52), the appearance of microalbuminuria may be less closely related to glucose levels per se, and interventions may reduce MA independently of glucose tolerance categories.

	NGT	IGT	Newly	Established
			diagnosed DM	DM
Niskanen	3%		18.2%	33%
Fujikawa	4.1%			
Collins	26%	43%	63%	75%
Standl			19%	
Olivarius	5.6%		32%	
Kuusisto	>20%			
Forsbloom		11.0%	10.0%	
Mykkanen	15.6% (+IGT)			
Giuzar			10.6%	

Table 4: Prevalence of Microalbuminuria

There are relatively few studies of neuropathy in IGT or newly diagnosed diabetes (65-76). The literature varies on whether there is an increased prevalence of neuropathy in IGT. Surveys suggest prevalence rates in IGT varying from 0.5 - to 3-fold those in NGT (11-16% absolute prevalence rates using clinical measurements). This suggests the possibility that neuropathy may begin to emerge in the prediabetic state. A major problem in these studies is the lack of a uniform test to diagnose neuropathy and the lack of longitudinal studies, especially in IGT population. The prevalence was 4-6 times greater in clinically newly diagnosed diabetic subjects (14-43%) compared to NGT (66,70,73) and about 7 fold greater in established diabetic subjects (65,73,76), but it was not increased in diabetic subjects identified in a glucose intolerance screening program (67). Progression in either newly diagnosed diabetic subjects or individuals with established diabetes without baseline neuropathy was 2-5%/year (70,71,72,74,75).

	NGT	IGT	Newly diagnosed DM	Established DM
Ratzmann				
-Abnormal T&PP*			14.7%	
-Loss of reflex			13.6%	
Sosenko		As NGT	As NGT	
Partanen	2%		8%	
Franklin (SLV)**	3.5%	11.2%		27.8%
Hoorn				
-Absent VS+	0.5%	16.2%	43.3%	68.5%
-Absent reflex	6.0%	15.6%	32.2%	67.1%
				6.6 years duration
Fedele				32.3%

#### **Table 5: Prevalence of Neuropathy**

\*Touch and pin-prick

\*\*San Luis Valley Study

+Vibrating sensation

Better understanding of the clinical course of IGT and Ty2DM from the time of onset is critical for several reasons. Establishing the precise relationship between glycemic levels and the occurrence of "diabetic" complications plays a significant role in determining the level(s) of glycemia at which diabetes is diagnosed and therapy is considered. Moreover, such knowledge will contribute to our understanding of the pathogenesis of diabetic complications. Among the major hypotheses to explain the pathophysiology of diabetic complications, the "glycation" hypothesis is probably the most in vogue and has the most mechanistic data associated with it. (77,78) Since glycation occurs not only in red blood cells and hemoglobin, but also in all tissues and circulating proteins exposed to glucose, it should come as no surprise that there may be no specific threshold where one finds diabetic complications; rather, there may be a continuum of risk associated with glycemia, including in the sub-diabetic range. Only through studies of prediabetic patients, i.e. IGT, and new onset diabetes, will we have the opportunity to explore the pathophysiology of diabetic complications.

#### 3.3.2. Epidemiology of CVD in IGT and New-onset Type 2 Diabetes

In addition to examining potential differential effects of the randomized interventions on CVD, atherosclerosis and CVD risk factors, further follow-up of the DPP cohort, with its IGT and newly diagnosed Ty2DM subjects, should shed light on the clinical course of CVD, atherosclerosis, and CVD risk factors in various states of glucose intolerance and during the transition from IGT to diabetes. Numerous studies have demonstrated that subjects with diabetes have a 2-4 fold increased likelihood of developing CVD. (11) It is generally believed that this increased risk for atherosclerotic vascular disease is driven by multiple risk factors, including dyslipidemia, hypertension, a procoagulant state and hyperglycemia itself, which frequently cluster in these individuals, linked together by insulin resistance and decompensating beta cell function. (14,28,29) The natural history of atherosclerotic vascular disease in IGT and diabetic

The Biostatistics Center, George Washington University Rockville, Maryland

subjects is not well understood. An increased risk for CVD in Ty2DM subjects is clearly present at the time of clinical diagnosis of diabetes. (30) Moreover, CVD risk factors associated with insulin resistance, such as higher blood pressure, and triglyceride levels, fibrinogen and PAI-1, and reduced HDL-cholesterol levels, are found in normoglycemic adult subjects who go on to develop diabetes 8 years later, compared to those who do not, suggesting that the substrate for the increased risk for atherosclerosis is present many years prior to the development of diabetes. Atherogenic risk profiles accompany increasing glycemia in the sub diabetic range. (28,29) However, little is known about the subclinical and clinical course of atherosclerosis during the period when glucose tolerance becomes impaired, followed by development of diabetes.

Most reported studies suggest that the risk for coronary heart disease (CHD) in IGT is intermediate between that in the general population and that in diabetic individuals. (14) However, some studies have not detected any difference in CHD frequency between normal glucose tolerance (NGT) populations and those with IGT, and others have found differences in men or women only. (13,31) Most of these studies were cross-sectional and many of the older surveys did not utilize the WHO diagnostic criteria to define IGT and are therefore difficult to interpret. Among prospective studies in subjects categorized into NGT and IGT groups according to WHO criteria, a Finnish investigation found no difference in CHD incidence. (32)

In addition to differences in the demographics, categorization of subjects, and study design influencing the apparent risk of CVD, the prognostic and metabolic heterogeneity of individuals with IGT inevitably must influence the intrinsic natural history of CVD in these subjects. Although there is little disagreement that Ty2DM is associated with a higher risk of CVD than is IGT, the reason(s) for these differences are not known. It is likely that those individuals with IGT who develop diabetes within a given period have a greater risk than those who do not; however, this has not been studied. Furthermore, there is no information about the risk factor profile or CVD incidence in newly converted diabetic subjects relative to those with IGT, or with longer duration diabetes. Finally, the relationships between established and newer CVD risk factors to subclinical and clinical CVD measures in subjects with IGT and newly diagnosed Ty2DM diabetes, and whether they differ between these two entities has not been studied. Of particular interest is whether glycemia per se is a determinant of increased CVD risk in subjects who convert from IGT to diabetes. Thus, a long-term prospective follow-up study of CVD risk factors, and subclinical and clinical measurements of CVD in a population with IGT, some of whom develop diabetes within the study period and continue to be studied, will provide critical information on the evolution of cardiovascular disease and the factors that influence it, in the preclinical phase of diabetes.

With the advent of the modified ADA diagnostic criteria (4) and the definition of the new category of impaired fasting glucose (IFG), several studies have suggested that IFG does not increase CVD risk compared to those with NGT (33) or alternatively that IGT increases susceptibility for CVD significantly more than IFG (34,35) does. In addition, in a recent large prospective study, HbA1c was continuously correlated with CVD mortality within a non-diabetic population. (36) Lastly, some studies have suggested that post-challenge glucose levels are more predictive of CVD than are fasting glucose levels in those with diabetes or impaired glucose tolerance. (37,38) In none of these studies was any attempt made to assess the unfolding role of the evolution of diabetes in non-diabetic subjects, which is clearly a crucial issue in attempting to clarify the nature of the relationship between glycemia and CVD over time.

DPPOS provides the opportunity to examine CVD, atherosclerosis, and CVD risk factors in a large, demographically diverse, prospectively studied population with IGT and newly

diagnosed diabetes. Repeated measures of glycemia and CVD risk factors during and after the DPP make possible a large number of analyses that have never been possible before. By extending this assessment for a further 5-10 years, there should be a sizable group of diabetic subjects who will have been studied through a phase of IGT and into a phase of diabetes, each lasting several years. Since the date of development of diabetic hyperglycemia is known within 6 months, it will be possible for the first time to track CVD risk factors, and subclinical and clinical outcomes as a function of this transition.

The DPPOS cannot strictly be viewed as a natural history study of IGT, nor of "undiagnosed diabetes" since both of these groups of subjects will have received more study- as well as non-study-based treatment in DPP and in the post-DPP period of follow-up than would occur naturally in the population. However, it is entirely possible that the most important determinant of CVD incidence in our entire study population may be found to be whether participants develop diabetes or not, irrespective of the interventions they have received. Such a finding would be of great importance to the conception of diabetes prevention. In addition, the relationships found to exist in this study between CVD risk factors and CVD subclinical and clinical outcomes will be informative, independent of interventions. We will carefully assess concurrent medication use during the follow-up study, since several effective medications for hypertension, dyslipidemia, and renoprotection are now available and will increase in use over time. Since there is evidence that blockade of the angiotensin system may slow progression to diabetes use of these agents will also be assessed (39,40).

#### 3.3.3. Summary

In summary, the DPPOS provides the opportunity of addressing the clinical course of IGT and new onset Type 2 diabetes as it relates to microvascular disease and neuropathy. Specifically, the epidemiologic part of DPPOS will address the following: the level of glycemia at which retinopathy, neuropathy, and nephropathy develop; the incidence of complications in IGT and truly new onset Type 2 diabetes; the effect of conversion from IGT to diabetes on the development of these complications; the relative effects of fasting and post-prandial glucose levels and HbA1c on risk for developing complications; and the interactions among glycemic and non-glycemic risk factors on the development of the complications. In these epidemiological analyses, previous DPP therapy assignment will be included as one of many covariates.

#### 3.4.Effects of Race-ethnicity and Gender

Over 45% of the DPP participants belong to a US minority racial or ethnic group: at baseline, 19.9% were African American, 15.7% Hispanic American, 5.3% American Indian, and 4.4% were Asian American. The majority of clinics enrolled >25% of participants from at least one non-Caucasian group. The major DPP study results suggested that the active interventions were effective across all racial-ethnic groups in the study, based on a negative test for heterogeneity. (4) However, the same questions posed for the entire DPP cohort in DPPOS are highly relevant in the individual ethnic-racial groups. The long-term effects of DPP interventions on clinical outcomes and the clinical course of IGT and new-onset Ty2DM is especially important in the minority populations because of the increased prevalence of Ty2DM in these groups, compared to the general population (6,78-83), and the suggestion, based on limited data, that the clinical expression of diabetes with regard to complications may be different between

The Biostatistics Center, George Washington University Rockville, Maryland ethnic-racial groups. The long-term follow-up may shed light on ethnic-specific contribution of vascular risk factors for the development of micro- and macrovascular complications associated with diabetes or IGT. Similarly, there are limited data regarding the impact of gender on the development of diabetes and its complications. Finally, though epidemiological studies have characterized the prevalence of diabetes in minority racial/ethnic populations, such studies have generally not provided ethnic, age, or sex-specific incidence rates. The highly compliant and motivated DPP cohort represents an excellent opportunity to examine these issues.

# **3.4.1.** Risk Factors for Type 2 Diabetes and Diabetes-related Complications in Minority Populations

Risk factors for diabetes and its vascular complications such as IGT, decreased insulin sensitivity, hyperinsulinemia, central obesity, overweight, hypertension and gestational diabetes are more prevalent in African Americans. (84) Diabetic retinopathy also appears to be more common in African Americans with Ty2DM (85), though it is not clear whether the higher prevalence of diabetes is responsible. In the cross-sectional Baltimore Eye Study, there were equal rates of blindness secondary to diabetic retinopathy in Blacks and Whites. (86) Other studies have reported the prevalence of blindness to be twice in Black compared to White individuals and of severe visual impairment to be 40% higher among African Americans. (87) The prevalence of retinopathy in Blacks with Ty2DM in the 1988-1991 phase of NHANES III was higher than the rate in non-Hispanic Whites (NHW) but similar to that in Mexican Americans, though these data may reflect the higher rates of hypertension and poor diabetes control. (87)

Similar confounders complicate the interpretation of the 2.6 to 5.6 fold higher rates of end-stage renal disease (ESRD) in Black compared to White Americans with diabetes. (88) Complications of diabetes including retinopathy, nephropathy, ESRD, lower extremity amputation (LEA), heart disease and stroke are all more prevalent among American Indians than among Whites. (80) Complications of diabetes among Hispanics have largely been studied in Mexican Americans. The San Antonio Heart Study and NHANES III reported a greater prevalence of microvascular complications with 4.5 to 6.6 fold higher rates of ESRD than the general diabetic population and diabetic retinopathy being ~2 times more frequent in Mexican Americans, though this has not been confirmed in all studies. (88-90) These data regarding ESRD cannot be easily extrapolated to milder degrees of nephropathy.

Diabetic neuropathy is inherently difficult to study since measurement of nerve dysfunction has not been commonly performed in large epidemiological cohorts. While lower extremity amputations (LEA) may be a robust marker for severe peripheral sensory neuropathy, it represents a late stage of disease, frequently coincident with peripheral vascular disease and is relatively infrequent.

Cardiovascular disease is the major factor underlying the high mortality rates observed in Ty2DM. It is generally accepted that CVD rates in African Americans with diabetes are lower than the rates in NHWs. (91) Lower rates of heart disease have been reported in Mexican American men, compared with NHW men, but not in Mexican American women compared with NHW women. (92)

In none of these cross-sectional reports are minorities and NHW as well matched for demographic characteristics, risk factors, and comorbidities as in the DPP. The longitudinal follow-up and careful characterization of the DPP cohort should help to delineate the risks of

developing diabetes and its long-term complications in men and women and in the ethnic-varied groups represented in the study.

# 4. DEFINITION OF OUTCOMES

## 4.1.Primary

# 4.1.1. Glycemia: OGTT and FPG (primary during Phase 1 and secondary during Phase 2)

The DPPOS primary outcome for Phase 1 and a secondary outcome for Phase 2 is progression of oral glucose tolerance test (OGTT) results to confirmed diabetes, by ADA criteria (5). To assess progression to this outcome, an OGTT will be performed routinely on an annual basis through year 12 under conditions described in the Manual of Operations. All biochemical laboratory outcomes will be measured at the DPPOS Central Biochemistry Laboratory. If the OGTT result meets ADA criteria for diabetes, the participant will be called back for a repeat OGTT within 6 weeks. In order to minimize the unmasking of participants and investigators to a positive but unconfirmed OGTT result, a subset of participants who do not have OGTT results positive for diabetes will be chosen by the Coordinating Center for repeat OGTT. If two sequential OGTTs, performed within a goal of 6 weeks of each other, are positive for diabetes, the clinic and the participant will be notified of the results and the participant will be considered as having reached the primary outcome. If the second test does not meet ADA criteria for diabetes (unconfirmed status), no such notification will be made and the participant will continue on the assigned treatment. In year 13, if HbA1c  $\geq$ 6.5% and fasting glucose is <126 mg/dl, a confirmatory OGTT will be performed. If the OGTT meets the diagnostic criteria for diabetes, the participant will be notified of the results and the participant will be considered as having diabetes. Otherwise, the participant will have not met the criteria for diabetes.

In addition, as a safety measure, participants will be monitored with a fasting plasma glucose (FPG) semi-annually through year 12 and annually in year 13 or at any time symptoms suggestive of decompensated diabetes are noted. If this FPG is  $\geq$ 126 mg/dL [7.0 mmol/L], the participant will be called back for a repeat FPG within 6 weeks. If the repeat is also  $\geq$  126 mg/dL [7.0 mmol/L], the participant will be considered as having reached the primary outcome, the participant and treatment team will be informed (see section 7.5.6), and an OGTT will be performed for data collection purposes to assess insulin secretion and sensitivity. Again, to maintain masking, the Coordinating Center will ask for a repeat FPG on a subset of non-diabetic participants with FPG < 126 mg/dL [7.0 mmol/L].

Finally, any participants who develop symptoms consistent with hyperglycemia will be encouraged to contact the clinic as soon as possible so that an FPG can be measured. If the FPG is  $\geq 126$  [7.0 mmol/L], the testing strategy outlined above will be followed.

Criteria for the primary outcome:

- 1 FPG  $\geq$ 126 mg/dL confirmed within a goal of 42 day interval
- 2 2 hour OGTT sample  $\geq$  200 mg/dL confirmed within a goal of 42 day interval
- 3 one FPG  $\geq$  126 mg/dL and one 2 hour OGTT sample  $\geq$  200 mg/dL on two separate visits within a goal of 42 day interval.

During Phase 2 of DPPOS, the further development of diabetes, and the effects of the original interventions on the development of diabetes over the entire course of the DPP/DPPOS, will remain important secondary outcomes.

### 4.1.2. Composite Diabetes-related Microangiopathic and Neuropathic Primary Outcome

The composite diabetes-related microangiopathic primary outcome for Phase 2 is defined as the presence of one or more of the following at the year 11 visit, or if the participant is deceased or lost to follow-up before Year 11, the presence of one or more of the following as of his/her last assessment:

- a. Nephropathy: micro- or macro-albuminuria (≥30 mg/gram creatinine, confirmed), or renal dysfunction (end-stage renal disease, dialysis or renal transplant) or GFR < 45 ml per min based on serum creatinine, using the CKD-EPI equation or another validated algorithm; the qualifying criteria confirmed)</li>
- b. Retinopathy: retinopathy by fundus photography (ETDRS grade of 20 or greater) or adjudicated history of laser or other treatment for retinopathy or
- c. Neuropathy: reduction or absence of light touch sensation to monofilament (Semmes-Weinstein 10 gram) in either foot (< 8 of 10 applications detected).

If a participant is taking antihypertensive drugs at the last assessment and does not meet the ACR or eGFR criteria at that time, he or she may be considered to have reached the nephropathy outcome if the nephropathy criteria were met at 2 consecutive past visits. This may substitute for the occurrence of nephropathy at Year 11.

#### 4.1.3. Composite Diabetes-related Cardiovascular Disease Secondary Outcome

The composite diabetes-related cardiovascular disease secondary outcome is defined as the time to first occurrence of one or more of the following: a) cardiovascular disease (CVD) events (CVD death, fatal and non-fatal myocardial infarction and stroke), b) silent myocardial infarction on EKG, c) coronary artery stenosis  $\geq$  50% documented by angiography, d) coronary revascularization, e) hospitalized CHF, f) hospitalized unstable angina/acute coronary syndrome, or g) revascularization or amputation in lower extremity not caused by major trauma.

CVD events are determined at the time of their report and classified and adjudicated by an outcomes committee whose members are blinded to treatment group.

#### 4.2. Other Secondary Outcomes

The DPPOS secondary outcomes were selected for their importance to the clinical and scientific interpretation of the study. They might help explain the mechanism of the primary outcome results, or shed light on how the interventions affect outcomes such as cardiovascular disease and its risk factors, which is at least as clinically meaningful as the primary outcome. Secondary outcomes may be assessed in the study population as a whole or in subsets of the study population, depending on feasibility, cost and the likelihood of deriving significant results from a subset. All biochemical laboratory outcomes will be measured at the DPPOS Central Biochemistry Laboratory. Clinical center staff and study participants are notified if a secondary outcome result falls outside a clinically acceptable range for that participant, constituting a concomitant condition. The timing of outcome assessments is described in Section 12.

Following is a brief summary of secondary outcomes that will be measured at specified intervals (see section 12) in all participants:

# 4.2.1. Glycemia and insulin secretion:

- HbA<sub>1c</sub>: Hemoglobin A<sub>1c</sub> will be assessed to reflect recent average glycemia, to test its relationship to OGTT results and its utility as an indicator of glucose intolerance for the purposes of diabetes prevention, and as a predictor of microvascular and macrovascular endpoints.
- Insulin and glucose measurements during the OGTT.

# 4.2.2. Cardiovascular disease and risks, assessed by:

- Electrocardiogram
- Cardiovascular symptom and disease assessment
- History of serious cardiovascular disease events
- Arm blood pressure
- Ankle/arm systolic blood pressure: Ankle-brachial index
- Coronary artery calcium
- Fibrinolysis and clotting factors: Fibrinogen, tissue plasminogen activator and C-reactive protein
- Lipoproteins: Lipid profile (total cholesterol, total triglyceride, HDL-cholesterol and derived LDL-cholesterol), or beta quantification in the setting of hypertriglyceridemia (specifically measuring LDL-cholesterol), LDL particle size and sub fractions
- Cardiovascular risk profile

# 4.2.3. Retinopathy, assessed by:

- Fundus photography
- History of documented laser surgery for diabetic retinopathy

# 4.2.4. Nephropathy, assessed by:

- Albumin excretion: Urinary albumin and creatinine concentrations for albumin excretion, using a spot collection.
- Serum cystatin
- Serum creatinine
- History of end-stage kidney disease treated with dialysis or transplantation

# 4.2.5. Neuropathy, assessed by:

- Semmes Weinstein 10 gram monofilament examination
- Symptom assessment
- Michigan Neuropathy Screening Instrument
- **EKG rhythm strip:** to measure heart rate variability

# **4.2.6.** Physical activity, nutrition, behavioral, and body mass and obesity, assessed by:

- Physical measurements: Height, weight, waist circumference, BMI
- **DEXA:** Measures of bone density and whole body composition in a sample of participants
- Physical activity: Standardized questionnaire assessment
- Nutrient intake: A semi-quantitative food frequency questionnaire.
- **Behavioral:** Dietary restraint, Exercise Self-Efficacy, Low Fat Diet Self-Efficacy

# 4.2.7. Health related quality of life, assessed by:

- **Psychosocial:** Beck Anxiety and Depression Inventories and the MOS SF-36, to assess mood and general adjustment and health related quality of life.
- Cognitive performance
- Physical functioning
- Urinary incontinence
- Activities of daily living and and Instrumental Activities of Daily Living (year 13 only)

# **4.2.8.** Resource Utilization, Costs, Health Utilities, and Effectiveness of treatments, assessed by:

- **Quality of Well-Being Scale:** A preference-based measure for overall health used for quality-adjusted life year's computations.
- **Resource utilization instruments:** Questionnaires to capture resource utilization from the perspectives of the participant, and of the DPPOS staff
- Hospitalizations

# 4.2.9. Safety tests:

- Routine chemistry testing: Annual serum creatinine
- Serious adverse medical events and symptoms: Queries for serious adverse events. Medical records will be gathered in the case of significant cardiovascular intercurrent medical events and reports of cancer diagnosis.
- **Pregnancy testing:** As needed for metformin-treated participants, based on symptoms and menstrual history.
- **CBC:** Annually, for metformin-treated participants, measured locally

# 4.2.10. Serologic evidence of type 1 diabetes, assessed by:

• Samples for IA2 and GAD antibodies at time of diabetes conversion

# **4.2.11. Stored specimens:**

• **Sample storage:** Samples of plasma, serum (year 13 only) and urine (year 13 only) will be stored for possible future analyses related to IGT and Type 2 Diabetes, and their complications. Samples for DNA were collected during the DPP.

# 4.2.12. Other chemistries:

• Relevant biological markers related to the pathogenesis of diabetes and its complications

# 4.2.13. Other research outcomes:

- Cancer incidence included to evaluate the potential changes in cancer risk with DPP therapies
- Other outcomes of the DPPOS include the incidence and determinants of these health outcomes in participants with new-onset diabetes and IGT, as well as the effect of age, race/ethnicity and gender on health outcomes.

# 5. STUDY DESIGN

# **5.1.Overall Design**

The DPPOS is a prospective study of the effects of DPP interventions on continued prevention or delay of diabetes, and on preventing or ameliorating its complications, specifically diabetic microangiopathy, neuropathy and cardiovascular disease. The rationale for the overall design is to provide maintenance of therapies found to be effective in DPP to assess the long-term impacts on diabetes prevention and complications.

All DPP participants were offered the opportunity to participate in the group lifestyle intervention protocol during the Bridge period, January through June 2002. They will be offered the opportunity to continue a long-term maintenance of lifestyle intervention program, consisting of quarterly Healthy Lifestyle Program (HELP) meetings through spring 2014. In addition, through spring 2014, DPP intensive lifestyle participants will be offered 4 weekly or bi-weekly behavior boost sessions in groups twice yearly, and DPP metformin participants will be provided open label metformin (850 mg bid) These are summarized below:

Treatment group name during DPP	Treatment group name during DPPOS
Intensive lifestyle intervention (ILS)	Boost Lifestyle (BLS)
Metformin with standard lifestyle (MET)	Metformin/Group Lifestyle (MLS)
Placebo with standard lifestyle (PLB)	Group Lifestyle (GLS)
Troglitazone with standard lifestyle (TRO)	Group Lifestyle (GLS) (will no longer be research
-	volunteers as of protocol version 3.0)

All DPPOS participants will have twice-yearly visits. Health outcomes assessment will include a brief medical history and fasting glucose measurements at the midyear interval, and an OGTT, HbA1c, questionnaires, and anthropometric measures and biochemical measurements annually. During DPPOS year 13, fasting glucose measurements at midyear visits and OGTTs at annual visits will be discontinued, mirroring the anticipated measurement structure of the planned continuation study. Fundus and neurologic examinations, and measures of subclinical atherosclerosis and cardiovascular events will be performed as stipulated in Section 12.

Assessment of microangiopathic and cardiovascular measures will be performed in both diabetic and non-diabetic DPP participants during all years of the DPPOS. Both individual and composite endpoints will be assessed. The long-term effects and cost-effectiveness of interventions on the incidence and determinants of these outcomes will be assessed based on the original randomly assigned interventions during DPP.

In addition to the primary and secondary objectives, separate analyses will be performed to assess the importance of development of diabetes and other determinants on the development of microangiopathic and cardiovascular outcomes. Subgroup analysis will be performed based on gender, age and race/ethnicity.

# **5.2.**Participation Criteria

All DPP participants will be eligible to participate in the DPPOS. For DPPOS protocols prior to version 3, participants included both diabetic and non-diabetic subjects from each of the four original intervention groups. Beginning with protocol version 3.0, the original troglitazone

participants will no longer participate in DPPOS research activities. Inability to attend group sessions for logistical or heath reasons will not be a criterion for exclusion.

### 5.3. Principles Guiding the Selection of a Study-wide Group Lifestyle Intervention

The decision to offer effective therapy to the DPP cohort at study end was based on the sense of the DPP Research Group and NIDDK that initiating effective therapy was consistent with our obligation to the participants who had made the DPP possible. Although this decision was not based on any scientific imperative, the Research Group did not think that it would interfere with the follow-up study as designed. Continuing to apply the DPP interventions during DPPOS was based on the expectation that a positive effect of DPP interventions on long-term health outcomes would more likely be obtained if the interventions that were effective in DPP were maintained to some degree in the DPPOS, recognizing that the DPP placebo group would now receive lifestyle intervention as well. This design for DPPOS was thought more likely to minimize confounding of the effects of the past DPP interventions through the introduction of non-standardized therapies by participants and their health care providers.

During the final six months of the DPP (January – June 2002) all participants in the original MET, PLB, and TRO groups were offered the Healthy Lifestyle Program (HELP), an intensive program with the same goals used in the DPP, but provided in a group, rather than an individual setting (DPP Bridge Protocol, version 4.5). During this period, the former ILS group continued with the DPP ILS program, albeit with less frequent contact than during the DPP, owing to resource limitations, and attended the HELP sessions if they desired. In DPPOS all participants will be offered quarterly group sessions to encourage the maintenance of their lifestyle interventions until June 2014. These meetings should, in addition, help to encourage continued participation in the DPPOS. The use of twice yearly behavior boost groups for the DPP ILS participants was intended during years 1-12 to reinvigorate their previous efforts at achieving weight reduction and increased physical activity in a manner that requires only modest staff involvement. Beginning in year 13, lifestyle messages will be reinforced during regularlyscheduled outcomes visits and at one annual HELP lifestyle class offered to all participants. Metformin will be provided to all participants who were receiving metformin treatment in DPP in order to maintain long-term intervention with this agent. Although the provision of lifestyle training to the DPP PLB group during years 1-12 may reduce differences in long-term outcomes between intervention groups, it is unavoidable. Moreover, the potential benefits of the active interventions during DPP on long-term outcomes, combined with efforts to boost the earlier impact of intensive lifestyle management, and continuing with metformin treatment, provide the opportunity to examine and compare the long-term effects of these interventions on an intentionto-treat basis.

#### 5.4. Timing and Condition of Outcomes Assessment

# 5.4.1. Development of Diabetes

During years 1-12 progression from impaired glucose tolerance (IGT) to diabetes is assessed by OGTT testing annually, or by fasting plasma glucose (FPG) at the intervening 6month visit, or any visit at which symptoms consistent with hyperglycemia are reported. During study year 13, progression from IGT to diabetes will be assessed with an annual fasting glucose measurement. Fasting glucose measurements at midyear visits and OGTTs at annual visits will be discontinued in year 13, mirroring the anticipated measurements in the planned continuation study. Conditions for the OGTT are specified in the Manual of Operations and remain unchanged from the DPP. The annual OGTT will be postponed for up to six weeks if a temporary concomitant condition exists that would affect glucose tolerance. An OGTT that is positive for diabetes, or a FPG that is  $\geq 126 \text{ mg/dL}$  [7.0 mmol/L], will be repeated for confirmation before the participant is considered to have developed diabetes. When a participant has been in a "time-out" (other than for pregnancy), such as for a concomitant disease known to affect glucose tolerance, the fasting glucose assessment or OGTT will not be assessed at the midyear or annual visit. Limited random repeat testing will be done to maintain masking to the occurrence of development of diabetes until the result of the confirmation test is available.

# 5.4.2. Other Outcomes

Individual and composite microangiopathy, neuropathy, cardiovascular, quality of life and health cost outcomes will be assessed according to the schedule listed in Section 12.

# 5.5.Masking

There will be no masking of participants to OGTT or lipid results, other than in the case where confirmation of a positive test for diabetes is pending (or during a random repeat fasting glucose or OGTT). Metformin is dispensed as open label.

# 6. PARTICIPANT MANAGEMENT PROTOCOLS

Each participant is asked to continue treatment according to his or her original DPP randomized assignment. Metformin will continue to be provided to the original Metformin participants during study year 13. The lifestyle HELP program will be held once annually and Boost programs will be discontinued beginning with year 13.

- Participants in the DPP original Intensive lifestyle intervention, now called the Boost Lifestyle (BLS), are offered the Healthy Lifestyle Program (HELP), plus the Boost Lifestyle program until the summer of 2014.
- Participants in the original Metformin group, now called Metformin/Group Lifestyle (MLS), are offered continued treatment with metformin, plus the HELP.
- Participants in the original Placebo group, now called the Placebo/Group Lifestyle (GLS), are offered the HELP.
- Participants in the original Troglitazone group, now called the Troglitazone/Group Lifestyle (GLS), are offered the HELP, but will not participate as research volunteers in DPPOS beginning with protocol version 3.0.

### 6.1.Schedule of Follow-up Visits

Follow-up visits for outcome measurements will be scheduled at 6-month intervals through year 12. Annual visits will be targeted for the anniversary of the participant's original DPP randomization date. HELP group meetings will be offered four times per year, at several different times at each clinic in order to make convenient meeting times available for a large number of participants and in the summer of 2014 HELP group meetings will begin to be held annually. Boost sessions will be offered twice per year, and similarly scheduled multiple times for purposes of convenience. Boost sessions will be discontinued beginning in year 13. Except for participants from the original Troglitazone group, who will cease study participation beginning with protocol version 3.0, all participants will continue their scheduled follow-up visits for the duration of DPPOS regardless of their level of compliance with the assigned treatment. Outcome and safety assessments will be conducted according to the schedule in section 12.

During study year 13, in-person annual visits will continue with reduced intensity of outcome measurements according to the year 13 outcomes schedule (See section 12). Mid-year visits will be brief, and may be held by phone or in person. The original DPP ILS participants will participate in an annual lifestyle check-up to reinforce lifestyle goals. Participants originally assigned to metformin who have not developed diabetes, or who have developed diabetes with an HbA1c <7%, will continue to be provided study metformin.

# 6.1.1. Interim Visits

An interim visit refers to all visits other than scheduled follow-up visits. Interim visits may be required for the monitoring or management of an emerging or existing medical condition, or to repeat procedures that were found to be deficient at a previous visit. Such visits may be held as frequently as deemed necessary.

## 6.1.2. Confirmation (CON) Visits

In order to confirm selected outcomes, confirmation (CON) visits are required whenever a participant has an elevated fasting ( $\geq$ 126 mg/dl), stimulated ( $\geq$ 200 mg/dl) glucose, or during year 13 an HbA1c  $\geq$ 6.5%. If albumin level  $\geq$ 30 mg/gm creatinine or eGFR < 45 is first demonstrated at the final (year 11) visit, participants will be asked to return so that a repeat urine or blood sample can be obtained for confirmation.

#### 6.1.3. Suspension of Follow-up Visits

The occurrence or presence of the following will constitute inactive follow-up and suspension of the scheduled follow-up protocol: Voluntary withdrawal by the participant, or a condition that, in the opinion of the principal investigator, makes it unsafe for the participant to continue. Efforts to return participants to an active status will be made regularly, as appropriate.

#### 6.1.4. Home or Telephone Visits

A home visit is any visit outside the DPPOS clinical center. Home visits will be used as needed and should not be used regularly to take the place of a clinic visit unless the participant is permanently unable to attend the clinical center. Local IRB issues should be addressed concerning off-site blood draws. All guidelines regarding the collection of outcome measures (such as fasting glucose) must be followed. A medical staff person who is certified to perform the listed outcomes should perform the home visit. The purpose of a home visit is to retain and /or reactivate participants and to collect important outcome data on participants who are having difficulty attending a clinic visit. Information on Serious Adverse Events will be collected at a home visit. In rare cases, the home visit may also be utilized to perform a safety blood draw when a medication participant is unable to attend a clinic visit. Home visits should only be conducted for participants who live relatively near the clinical center. Clinic staff is not expected to travel great distances to visit any inactive participant. Clinics will decide whether or not a specific home visit is feasible, taking into account time, cost and risk.

For those individuals who cannot travel and for whom a home visit is not possible, a telephone visit may be conducted to collect updated health history, Serious Adverse Events, CVD and cancer event information.

# 6.2.Lifestyle Program in DPPOS Years 1-12

Recognizing that long term adherence to healthy eating and exercise behaviors and maintenance of moderate weight loss and physical activity require ongoing support and intervention, lifestyle intervention efforts will be continued during the DPPOS for <u>all</u> previously randomized participants until the end of Phase 1, and for all but the former Troglitazone participants, who will not participate in DPPOS research beginning with protocol version 3.0. To maximize the chances of all participants achieving and/or maintaining the 7% weight loss goal and 150 minute weekly physical activity goal which was the cornerstone of the lifestyle intervention during DPP and the DPP Bridge, Healthy Lifestyle Program (HELP) maintenance sessions will be provided quarterly to all DPPOS participants through spring 2014 after which HELP sessions will be held once annually. In addition, participants who were previously
randomized to the intensive lifestyle arm in DPP will be given Boost Lifestyle Sessions in a group format, two times each year through spring 2014. The goals of lifestyle treatment for all DPPOS participants are the same as in DPP:

- Achieve a weight reduction of at least 7% of initial (at DPP baseline) weight and maintain this weight reduction
- Achieve at least 150 min/week of moderate intensity exercise (such as walking and bicycling), and maintain this level of physical activity

# 6.2.1. Lifestyle Resource Core and Lifestyle Advisory Group

The Lifestyle Resource Core (LRC) and the Lifestyle Advisory Group (LAG) which is comprised of co-investigators and staff representing several DPPOS centers will develop the materials for the HELP maintenance and BLS sessions and provide on-going training and support for the lifestyle interventionists. All materials are reviewed and approved by the DPPOS Executive Committee prior to implementation.

# 6.2.2. Staff for Lifestyle Interventions

Case managers, group lifestyle interventionists, and/or consultants at each clinical center will carry out both arms of the lifestyle intervention. Interventionists will be individuals with experience and/or training in nutrition, exercise, behavior modification, or group treatment. Other staff (e.g. peer counselors and exercise leaders) is employed as appropriate at each center.

# 6.2.3. HELP Program

Following the delivery of the 16 session Healthy Lifestyle Program (HELP) that was offered to all previously randomized participants during the DPP Bridge, quarterly HELP maintenance sessions will be offered to all participants until the summer of 2014. The purpose of the quarterly lifestyle sessions is to reinforce the basic content, as well as the weight loss and physical activity goals. In addition, the quarterly sessions will serve a participant retention purpose. Small incentives, such as gift certificates and lifestyle-relevant materials such as recipe books (gifts are valued in the range of \$2.00-10.00) will sometimes be used to reward attendance and participation at these group education sessions. Every effort will be made to make the sessions topical, interesting, and fun (e.g. may involve doing cooking demonstrations, muscle resistance training, stress management and relaxation training etc.) The quarterly sessions will rotate annually through the following content areas:

- Nutrition
- Physical activity
- Stress management/motivation/behavioral self-management
- Diabetes prevention research updates
- Diabetes research and management updates

Each of the four sessions will be offered up to 5 times in the quarter at each clinical center with approximately 20-40 DPPOS participants attending any one-class session. Topics

and lesson materials, handouts, and homework assignments are being developed by the Lifestyle Resource Core and will be outlined in detail in the Lifestyle Intervention Manual of Operations for DPPOS. The first quarterly session will begin within 2-3 months after DPPOS begins. After spring 2014, these sessions will be offered once annually.

# 6.2.4. Boost Lifestyle (BLS)

During the DPP Bridge period, DPP intensive lifestyle participants (ILS) either attended the HELP group sessions and/or were encouraged to be seen individually by their lifestyle case managers at least every 8 weeks. During DPPOS these participants will be offered Boost Lifestyle sessions in addition to Group Lifestyle sessions. The purpose of BLS is to offer periodic, structured "restarts" for lifestyle arm participants who have already received intensive, long-term, individual lifestyle intervention. The BLS sessions are intended to reinforce specific behavioral self-management activities (e.g., self-monitoring of fat, calories, and/or physical activity minutes as well as weight checks), which are important for weight loss and physical activity adherence and/or maintenance. An additional focus of the BLS will be to promote home-based behavioral self-management of weight and physical activity through the use of motivational campaigns. In addition to reinforcing attendance at group sessions, incentives (valued at \$5.00 - \$20.00) will also be used to reward lifestyle behavior change such as designated weight loss goals, activity goals, self-monitoring of diet and other healthy lifestyle changes. The BLS sequences for each clinical center are characterized as follows:

- The four session restart program will be offered over a period of 4-8 weeks
- A new sequence will be offered in the Spring and Fall of each year
- The program will be conducted in groups of approximately 10-20 participants
- Approximately 1-3 groups will be conducted during each Spring and Fall sequence, as necessary at each clinic to accommodate the BLS (former ILS) participants

Centers will be encouraged to help participants who have been working primarily in intensive, individual lifestyle treatment to make the transition to the group Boost sessions. However, if staff is available, they will be permitted to conduct individual visits, mailings, and/or phone calls to support lifestyle participants in making this transition to group intervention. Topics and lesson materials, handouts, and homework assignments to be utilized in BLS are being developed by the Lifestyle Resource Core and are in the Lifestyle Intervention Manual of Operations for DPPOS. The first BLS session will begin within 2-3 months after DPPOS begins. Boost sessions will be discontinued beginning in the summer of 2014.

# 6.2.5. Indices of Adherence

Adherence to the HELP program and BLS will be assessed in the following manner:

- Group contacts will be recorded primarily to assess attendance at both HELP sessions and BLS visits
- Adherence to the 7% weight loss goal is determined from measured body weight at mid-year and annual clinic visits for all participants

- Weight data and self-reported physical activity minutes will be collected at the BLS sessions
- Performance of physical activity is determined from interviewer administered questionnaires that assess physical activity at annual clinic visits for all participants

#### **6.3.Metformin Pharmacological Treatment**

#### 6.3.1. Description of Intervention

The pharmacological intervention is metformin 850 mg bid, as tolerated. DPP participants who had been randomized to active metformin and are still eligible to take medication will remain in the medication arm of the follow up study. This will allow the longest possible period of continued exposure to metformin to determine its longer-term effects.

Participants who are not eligible to continue study-supplied metformin are those who cannot tolerate metformin, whose creatinine is outside the normal range, who reached the fasting hyperglycemia ( $\geq$ 140 mg/dL) outcome during DPP, who have been taken off metformin for other medical reasons, and/or those who have diabetes and whose HbA<sub>lc</sub> was measured  $\geq$ 7% by the DPPOS Central Biochemistry Laboratory. Metformin is an investigational drug for the treatment of IGT and is used under an Investigational New Drug (IND 49,782) application with the Food and Drug Administration (FDA).

#### 6.3.2. Mechanism of Metformin Action

Metformin is an antihyperglycemic drug of the biguanide class used in the management of Type 2 diabetes in over 90 countries for over 30 years. It was approved for use in the U.S. in 1995 and is distributed by Bristol Myers-Squibb under the trade name Glucophage, and manufactured by Lipha, a French pharmaceutical firm. Generic products are now available as well.

Metformin reduces the excess hepatic glucose production that characterizes Type 2 diabetes without increasing insulin secretion. With reduced hyperglycemia, glucose uptake by muscle and other insulin sensitive tissues is enhanced while insulin levels remain stable or decline. In addition to its antihyperglycemic action, metformin also has antihyperlipidemic effects; particularly the lowering of serum triglyceride levels and is associated with weight loss.

Metformin has been found to cause lactic acidosis rarely (about 0.03 cases per 1,000 person years) and then only when used in persons with renal or hepatic insufficiency or during episodes of hypoxia or circulatory failure.

Before its 1995 release in the U.S., and after review of extensive metformin use in Canada, Europe and other parts of the world, Bristol-Myers Squibb issued an FDA approved package insert providing detailed contraindications, precautions and safety monitoring recommendations for its use in Ty2DM. During the DPP all of these recommendations (including periodic assessment of serum creatinine) were strictly adhered to and the maximum dosage used (1.7 gm/day) was less than the maximum recommended (2.55 gm/day).

Metformin is not currently approved for use as a preventive medication for the development of Ty2DM. However, the DPP demonstrated that metformin is effective in persons with impaired glucose tolerance, reducing the development of diabetes by 31%.

The most common side effects associated with metformin are gastrointestinal. As many as 30% of persons report diarrhea, nausea, metallic taste, abdominal bloating, flatulence or anorexia. These symptoms are generally transient, resolve spontaneously and can be avoided by gradual escalation of dosage. Metformin is not associated with hypoglycemia unless used in conjunction with other glucose-lowering medications (sulfonylurea or insulin). About 4% of participants were unable to continue metformin in U.S. clinical trials.

About 6-9% of persons on metformin develop reduced vitamin B12 levels. However, megaloblastic anemia is rare and metformin use has not been reported to cause peripheral neuropathy.

#### 6.3.3. Dosing Schedule and Restarts

Administration of metformin will be 850 mg twice each day, taken with food, and with doses recommended to be at least eight hours apart.

If a participant has a lapse in treatment due to illness, hospitalization or other cause and is eligible to restart the medication, then a plan for restart and titration should be considered. This plan should be based on clinical judgment taking into account the amount of time off metformin and the individual's history of side effects.

# 6.3.4. Safety Monitoring and Measures to Reduce and Manage Potentially Drug related side Effects

A. Laboratory Safety Monitoring

During the DPPOS all participants assigned to open label metformin will have an annual CBC with differential count and serum creatinine. Women in the metformin treatment group will be asked to get immediate pregnancy testing if their menstrual cycles are more than one week overdue or they otherwise suspect they are pregnant.

B. Potential Non-Gastrointestinal Side Effects

Potential non-gastrointestinal side effects include, but are not limited to: headache, mild edema, leg cramps, arthralgia, myalgias, dizziness, mild rashes, and dysmenorrhea. If nongastrointestinal side effects considered likely to be due to metformin occur and require cessation of metformin, it will be stopped for four weeks. If the non-gastrointestinal symptoms disappear, a second attempt to introduce medications is made after the four weeks. If symptoms re-occur, the metformin will again be discontinued. Clinical judgment should be used to decide continuing attempts. The plan for restart and titration of metformin is based on clinical judgment taking into account the amount of time off metformin and the individual's history of side effects. See the Manual of Operations (MOO) for suggested steps for restart.

C. Discontinuation of Metformin Use During Hospitalizations

Metformin should not be used in patients with hypoxia or circulatory failure and should be discontinued before the administration of contrast dyes and surgery requiring general anesthesia. To avoid having metformin administered inadvertently to hospitalized participants in whom it may be contraindicated, medication will be discontinued during hospitalizations. Testing of glucose tolerance for DPPOS will be delayed until medication has been resumed for at least two weeks. However, glucose tolerance testing will be performed within 6 weeks even if medication has not been restarted, assuming that the subject does not have a concomitant condition that substantially interferes with glucose tolerance. If the participant has a serious condition (e.g., recovering from major surgery, on high doses of steroids, ongoing febrile illnesses) known to affect the glucose tolerance adversely, the testing will be postponed until the next regularly scheduled testing of glucose tolerance. Participants will have a GTT or FPG at least annually.

# D. Gastrointestinal Symptoms

These symptoms include diarrhea, abdominal pain, vomiting, nausea, a metallic taste, bloating, flatulence and anorexia. If these symptoms are mild and tolerable, medications will be continued. If they are moderate or difficult to tolerate, they will be presumed initially to be due to metformin and metformin will be withheld, at least temporarily. In the event that diarrhea, abdominal pain or vomiting becomes severe enough to cause dehydration or volume depletion, metformin will be discontinued immediately and the participant will be evaluated and treated appropriately.

# E. Renal Insufficiency

Serum creatinine safety measurements will be made yearly in participants in the metformin arm who are taking metformin. Metformin is not known to cause renal insufficiency. However, it is associated with an increased risk for lactic acidosis if used in persons whose glomerular filtration or creatinine clearance rates are below 60 mL/min (per 1.73 m<sup>2</sup> surface area). Thus, metformin use is contraindicated with serum creatinine  $\geq 1.5$  mg/dL [133 µmol/L] in men and  $\geq 1.4$  mg/dL [124 µmol/L] in women. If creatinine levels are high, metformin will be discontinued and the serum creatinine will be rechecked in two weeks. Metformin will be restarted if the repeat serum creatinine is < 1.5 mg/dL in men or < 1.4 mg/dL [124 µmol/L] in women, regardless of the cause, metformin will be stopped permanently and participants will be referred to their health care providers for an evaluation of potential causes of elevated creatinine. For participants who are permanently off study medication, elevations in serum creatinine do not require confirmation, but will be reported to the health care provider.

# F. Anemia

A CBC will be determined for safety reasons at yearly intervals in participants in the metformin treatment group who are taking metformin. If anemia (defined as a hematocrit < 36.0% in men and < 33.0% in women) or significant macrocytosis develop, or if the hematocrit decreases by 4 or more points from the level at study entry (e.g., from 44% to 40%) the participant and primary care provider will be notified. Medication may be continued if the cause of the anemia is identified and treated. This includes the administration of vitamin B-12 when indicated.

# G. Pregnancy and Nursing

Female DPPOS participants of childbearing age who are fertile have been informed of the potential risks to a pregnancy conceived while on metformin treatment. These women will be asked to practice reliable birth control including systemic hormones, intrauterine devices or barrier methods (diaphragm, male or female condom, cervical cap) with concomitant intravaginal spermicide.

Women in the metformin treatment group will be asked to get immediate pregnancy testing if their menstrual cycles are more than one week overdue or they otherwise suspect they are pregnant. If a woman plans to become pregnant or becomes pregnant, metformin will be discontinued. Following the pregnancy and nursing, metformin will be restarted with consideration of titration from one 850 mg tablet to two tablets over four weeks. See the Protocol Section 7.5 for more details about metformin use following pregnancy.

#### H. Radiological Studies Using Contrast Dyes

Because of the potential danger of contrast induced renal insufficiency and lactic acidosis associated with metformin, under these conditions, the last dose of medication will be administered on the day prior to administration of contrast dyes. Serum creatinine level will be checked 48 hours or more after dye administration. Metformin will be re-started if the serum creatinine levels are in the acceptable range (< 1.5 mg/dL (133  $\mu$ mol/L) for men and < 1.4 mg/dL (124  $\mu$ mol/L) for women). A wallet ID will be given to all participants and a warning letter will be sent to all primary care providers to alert them to the fact that participants are taking metformin and that metformin needs to be discontinued prior to any radiological studies involving contrast dyes.

I. Lactic Acidosis

Metformin may rarely be associated with the development of lactic acidosis, defined as a metabolic acidosis with lactate  $\geq 5.0$  mM. If hospitalization or an unexplained metabolic acidosis occurs, metformin will be discontinued immediately and not restarted. The participant will be evaluated and treated appropriately.

J. Hypoxic States - Congestive Heart Failure

States of hypoxia or hypo perfusion, including acute congestive heart failure and acute myocardial infarction, may lead to lactic acidosis and require discontinuation of metformin and treatment of the underlying condition. If the underlying hypoxic state is corrected or if CHF is transient (for example, after an acute MI), reinstitution of medication may be considered. Medication arm participants who develop CHF (NYHA Functional Class > 2) during the study should have their metformin stopped. Medication arm participants who develop NYHA Functional Class 2 and require a loop diuretic or digitalis should have their metformin stopped. K. Surgical Procedures

Because of the risk of metabolic acidosis during general anesthesia and major surgical procedures, medication will be suspended prior to such anticipated surgical procedures, with the last dose administered on the day prior to surgery. Medication will obviously be held while participants are NPO for procedures. Serum creatinine should be checked 48 hours or more after such procedures and medication will be restarted if the serum creatinine levels are in the acceptable range < 1.5 mg/dL (133  $\mu$ mol/L) for men and < 1.4 mg/dL (124  $\mu$ mol/L) for women). If an outpatient procedure is scheduled, a letter will be sent to surgeons to alert them to the fact that medication must be discontinued prior to surgery.

L. Dermatological Reactions

In the event of major dermatological reactions such as generalized urticaria, bullous rashes, exfoliative dermatitis or Stevens Johnson Syndrome, medication will be discontinued immediately and not restarted. For localized skin reactions, medication may be discontinued if the skin reactions are potentially drug related. If the rashes clear, medication may be restarted after four weeks, starting at the Step I dosage level and then progressing to Step II after another four weeks. If localized skin reactions recur with restarting the metformin, metformin should be discontinued.

# M. Headaches

Metformin has sometimes been associated with transient headaches, although not more frequently than placebo. However, headache is not a reason to decrease or discontinue the metformin unless severe and no other causes are found.

# 6.3.5. Indices of Adherence

The goal of the pharmacological treatment is to optimize adherence to the pharmacological regimen, while maximizing retention of participants in the DPPOS. Assessment of adherence to the prescribed medication will provide clinic staff a means to identify participants having problems with adherence.

The following will assess adherence to the pharmacological treatment:

- Visual inspection of participant's returned pill containers including a pill count estimating the percent of prescribed medication taken.
- A brief, structured interview, during which the case manager will assist participants to identify problems with adherence to metformin and to develop strategies to promote adherence, as needed.

#### 7. DEFINITION AND MANAGEMENT OF CONCOMITANT CONDITIONS

Clinical centers are neither sufficiently staffed nor funded to provide primary care or ancillary care to participants involved in DPPOS. The study recommends that participant health issues be followed by a primary care provider. Treatments for concomitant conditions can potentially affect either the primary or secondary study outcomes. The following sections provide recommended guidelines for select study outcomes. If the participant consents, laboratory and medical results are communicated in writing to the primary care provider. Implementation of these guidelines is left to the discretion of the primary care provider.

#### 7.1.Hypertension

There is a strong association between type 2 diabetes and hypertension, apparently independent of age and obesity (93). The baseline characteristics of the DPP cohort reveal 29% of men and 26% of women with a history of hypertension at entry. These percentages varied by ethnicity, with African American men as high as 35% and Hispanic women as low as 20%. Following are recommendations for treatment:

# 7.1.1. Goals of Therapy

For those individuals developing diabetes during the course of DPPOS, the study recommends therapy aimed at meeting the Standards established by the American Diabetes Association (94). For those participants who have not developed diabetes, the study recommends the goal of therapy for hypertension be consistent with the current recommendations of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure (95).

#### 7.1.2. Outcome Assessment

Outcome assessment for the categorical outcome of hypertension as well as the continuous variables of blood pressure will be undertaken semi-annually during years 1-12, and annually during year 13 of DPPOS. The DPPOS staff will communicate blood pressure readings to the participant and to the health care provider for follow-up and possible treatment.

# 7.2.Hyperlipidemia

A fasting lipid profile, consisting of triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol and VLDL-cholesterol will be obtained at annual visits (Years 1-12).

# 7.2.1. Diabetic Participants

The National Cholesterol Education Program (NCEP) guidelines call for identification of those individuals with established diabetes to be automatically placed in the same high-risk group as those with established CVD. The study recommends lipid lowering therapy be consistent with current ADA guidelines (96).

# 7.2.2. Non-diabetic Participants

For those individuals in DPPOS who have not developed diabetes, the study will recommend therapy consistent with the guidelines established by the NCEP (97) and the American Heart Association (98).

# 7.3.Cardiovascular Disease

Cardiovascular disease events have been chosen to be one of the secondary outcomes in DPPOS. The incidence of CVD is increased n participants with newly diagnosed Ty2DM, and the risk of deaths in non-diabetic participants with IGT is two times higher than in participants with normal glucose metabolism. Although the CVD event rate during the course of the DPP was quite low and showed no effect of randomized therapy, long-term follow-up may reveal differences based on DPP assignment as incidence of CVD increases with age. CVD events in participants recruited to the DPPOS are significant for several reasons:

- CVD outcomes might be differentially affected by the assigned interventions,
- CVD may have an effect on prognosis of the participants recruited,
- The symptoms of CVD may have an effect on the capability of participants to follow the guidelines of treatment, and
- The conversion rate from IGT to Ty2DM may be higher in participants with CVD than in participants without CVD.

Mid-year and annual history will ascertain the incidence of new CVD events as was performed during the DPP. ECGs will be obtained at the annual visits during years 1-12 for central reading and adjudication of silent infarcts.

# 7.3.1. Myocardial Infarction or Unstable Angina

Their PCP according to the community standards should treat participants who have myocardial infarction or unstable angina during the DPPOS. The decision whether participants are allowed to continue the exercise program or whether their exercise program should be modified is based upon the recommendation of their primary care providers.

# 7.3.2. New Angina Pectoris

Participants who have new symptoms suggesting angina pectoris during the DPPOS should be treated by their Primary Care Providers (PCP). DPPOS will recommend to the primary care provider that participants be treated according to the community standards including cardiological evaluation and possible exercise tolerance testing may be recommended to them. Participants will have their exercise program discontinued until the cardiological evaluation has been performed and their eligibility to continue the exercise protocol should be reconsidered after the results of the evaluation are available.

# 7.3.3. PTCA or Coronary By-Pass (CABG)

According to the American Heart Association Guidelines, exercise tolerance testing should be performed in the routine follow-up of patients who have undergone PTCA, and to any patient who complains of chest pain during exercise after these procedures. Participants of

The Biostatistics Center, George Washington University Rockville, Maryland DPPOS who undergo PTCA or CABG should be allowed to discontinue the exercise component of the DPPOS protocol for up to six months, if necessary. After this period their health status should be re-evaluated by their primary care provider to determine their continuation in the exercise portion of the protocol.

# 7.3.4. Medical Treatment

The participant's PCP will determine medical treatment of CVD. Beneficial effects of betablockers and ACE inhibitors on mortality and recurrent CVD events after myocardial infarctions are clear.

#### 7.4.Psychological Diseases and Use of Psychoactive Agents

Certain psychiatric disorders, including depression, can affect behavior and may affect glucose metabolism. Some drugs used to treat psychiatric disorders, including antidepressant medications such as those in the tricyclic and SSRI classes, can affect appetite, weight, and glucose metabolism. The presence of depressive symptoms among DPPOS participants was monitored by means of annual assessment during years 1-12 using the Beck Depression Inventory (BDI). Use of antidepressant medications will be monitored during clinic visits, and use will be noted as a confounding variable in relevant data analyses.

# 7.5. Pregnancy and Contraception

Women with a history of gestational diabetes (GDM) are a substantial subgroup of the DPP. Some of these women, together with other participants in DPP, will be of childbearing potential during the course of the DPPOS. Data from available cohorts suggest that about 6 percent of women of childbearing age may be expected to get pregnant each year.

Female DPPOS participants of childbearing age who are fertile have been informed of the potential risks to a pregnancy conceived while on metformin treatment. These women will be asked to practice reliable birth control including systemic hormones, intrauterine devices or barrier methods (diaphragm, male or female condom, cervical cap) with concomitant intravaginal spermicide.

# 7.5.1. Safety Monitoring

Women in the metformin treatment group will be asked to get immediate pregnancy testing if their menstrual cycles are more than one week overdue or they otherwise suspect they are pregnant.

# 7.5.2. Use of Study Interventions During Pregnancy and Breast-feeding

Metformin is contra-indicated in pregnancy although data on adverse effects on the fetus or the mother are scant. The embryo toxic effects of biguanides have been evaluated in the *in vitro* cultured mouse embryo model (99). Because of the lack of teratogenicity of metformin in the few available studies, this drug is classified by the FDA as pregnancy category B (no evidence of risk in humans, animal findings negative). In recently reported studies, metformin

has been shown to increase fertility in women with PCOS and some practitioners are investigating potential benefits of continuing its use during gestation. In the absence of definitive evidence indicating the safety of this practice, we will continue to recommend that during pregnancy and for the duration of breast-feeding; metformin should be discontinued in DPPOS participants.

There is no general contraindication for women continuing the recommended levels of exercise during pregnancy (100). The 150-min/wk target for activity levels should not require added monitoring during pregnancy, but because of the lack of data on ketosis with vigorous exercising, regimens that exceed 1000 kcal per week of energy expenditure may require monitoring of ketosis. Recommendations that exercise should continue with a target of 150 min/wk will be forwarded to the providers of obstetrical care for participants who get pregnant during the course of the DPPOS.

Dieting for weight loss during pregnancy can be dangerous; therefore, guidelines for calorie intake for healthy pregnancy and lactation (100) will be recommended. The recommended average daily caloric intake for pregnant women is 30-35 kcal/kg ideal body weight. These recommendations will be forwarded to the provider(s) of obstetrical care for participants who get pregnant during the course of the DPPOS.

The lifestyle intervention, with caloric requirements adjusted to account for breastfeeding, can be introduced as soon after delivery as is feasible; we recommend within the first month. Women who choose not to breast-feed should return to their pre-pregnancy lifestyle intervention, including dietary targets, within the first month following delivery. For women who choose not to breast feed, weight targets should return to pre-pregnancy levels regardless of extra weight that may have been gained during pregnancy. For women who breast-feed, weight targets should be suspended until lactation is finished and then should be re-established at prepregnancy levels.

#### 7.5.3. Outcomes Assessment Following Pregnancy

Participants who become pregnant during the DPPOS are likely to develop gestational diabetes, and many of these women will require insulin. The standard of care for follow-up after gestational diabetes is to assess glucose tolerance at six to eight weeks post-partum. Women who become pregnant during the DPPOS will have outcome assessments suspended until 6-8 weeks following delivery. This outcome measure following pregnancy will always be an OGTT. They will then attend the next regularly scheduled outcome assessment visit based on their original DPPOS follow-up schedule. Women meeting ADA criteria for diabetes will have reached the DPPOS primary outcome.

For those DPPOS participants who require insulin during pregnancy, assessing the ongoing need for insulin should begin in the hospital immediately post-partum. Women discharged on insulin should be evaluated with home glucose monitoring, followed by their providers of obstetrical care, to determine the ongoing need for insulin. Based upon post-partum monitoring, some women may remain on insulin or be started on oral hypoglycemic agents by their obstetrical/primary care provider(s). Participants treated with insulin or oral agents will not be re-started on their metformin unless and until their need for therapy resolves.

There may be some women who are still being treated by their primary care provider(s) with insulin or oral agents at the time of their first outcome assessment following pregnancy (i.e., 6-8 weeks following delivery). To ensure standardized assessment of outcomes, therapy must be

stopped for the OGTT. If cessation of therapy is not possible, two elevated fasting plasma glucose determinations may be used to define an outcome of diabetes in place of the OGTT.

#### 7.6.Smoking

The prevalence of smoking among the people with IGT is estimated to have declined to about 20 - 25% and is consistent with overall reduction in smoking in the U.S (101). Although 800-1000 of the original DPP participants were expected to be current smokers at the time of randomization, only 7% (approximately 250) of the participants were current smokers at baseline.

DPPOS will continue to follow established public health policy to reduce the prevalence of smoking by discussing smoking as a compounding risk factor for CVD and emphasizing the overall benefits to health for those who quit. DPPOS will emphasize to participants that the risks associated with smoking far outweigh the risks associated with weight gain associated with quitting smoking but will also note that exercise and healthy diet are excellent ways to minimize or eliminate that weight gain.

Following recommendations from the National Cancer Institute and the Agency for Healthcare Research and Quality, DPPOS staff will ask participants about smoking and provide brief messages encouraging them to quit. For those expressing interest in quitting, staff will provide printed materials and/or referral to primary care providers or community based programs. Through regular DPPOS visits, staff will follow up to encourage and support continued abstinence or further attempts to quit.

#### 7.7.Type 2 Diabetes

#### 7.7.1. Interim Visits for Symptoms

Following enrollment and randomization in the DPPOS, participants will be seen on a semi-annual basis for assessment of adverse events. If a participant develops symptoms consistent with uncontrolled hyperglycemia, he or she will be instructed to come to the clinical center for assessment of an adverse event and undergo a fasting plasma glucose determination. This test may be performed locally if needed for safety reasons; however, a sample must be sent to the CBL for outcome assessment. If the centrally read fasting glucose is  $\geq 126 \text{ mg/dL}$ , a repeat test will be performed within 6 weeks to confirm the diagnosis. The participant will have reached the DPPOS primary outcome if fasting glucose  $\geq 126 \text{ mg/dL}$  persists.

#### 7.7.2. Intervention and Follow-up for Participants with Diabetes

Participants, investigators, and primary care providers will be unmasked to the diagnosis of diabetes. The participant and the primary care provider will be informed of the diagnosis and the significance will be explained. It will be recommended that the PCP see the participant at one and three months following diagnosis and scheduled thereafter by the PCP. Participants will be offered self-monitoring of blood glucose (SMBG) with the option of monitoring glucose levels routinely two to three times weekly as well as during any acute illness or in the event of symptoms such as polydipsia, polyuria or polyphagia. SMBG results may be reviewed at mid-year and annual visits. DPPOS participants will continue to be seen at six monthly intervals

during years 1-12 and annually during year 13 for clinical assessment, and fasting glucose and hemoglobin  $A_{1c}$  determinations will be obtained and sent to the CBL. Secondary outcome measurements will continue to be performed as scheduled.

All participants will be encouraged to attend the group lifestyle sessions to reinforce the intervention that they have received. Subsequent individual reinforcement of standard lifestyle recommendations will occur at the scheduled annual visits. For persons taking study assigned metformin, the investigator, in conjunction with the primary care provider, will endeavor to maintain the participant on assigned metformin as long as the hemoglobin  $A_{1c}$  remains <7%. In the event that a participant progresses to a hemoglobin  $A_{1c} \geq 7\%$ , study metformin will be discontinued. In all participants with diabetes, when the hemoglobin  $A_{1c}$  is  $\geq 7\%$ , a stepped care protocol for treatment of diabetes mellitus, as recommended by the American Diabetes Association, will be recommended to the primary care provider.

#### 7.8. Retention Monitoring and Recovery of Inactive Participants

Retention of participants throughout the study period is key to both the power and generalizability of DPPOS findings. Retention of DPPOS participants will be encouraged through the provision of social support from DPPOS staff during clinic visits, group lifestyle meetings, and other incentives. All participants receive an honorarium, at scheduled visits, in recognition of the time and effort spent in the DPPOS.

Monitoring activities that track participants' attendance at scheduled clinic visits guide efforts to maximize retention. Missing semi-annual and annual data collection visits triggers a graded hierarchy of recovery efforts designed to maintain participants' involvement in DPPOS.

#### 7.9. Determining Vital Status and Cause of Death for Participants

The National Death Index (NDI) will be used to search for DPP and DPPOS participants who have not been seen at their local center and have not been able to be contacted for more than 1 year, as well for deceased participants. The NDI is a central computerized index of death record information from State vital statistics offices nationwide. Each center will submit their cases to the NDI. Coding that includes cause of death will be obtained. Records will be searched for all years for which vital status cannot be confirmed. Follow-back investigations will be undertaken to obtain medical records and next-of-kin interviews as required. Central review of cause-of-death will be adjudicated by an outcomes committee whose members are blinded to treatment assignment.

# 8. ADVERSE EVENT REPORTING

# 8.1.Definitions

Only adverse events meeting the criteria for serious will be ascertained and reported following FDA guidelines. Serious adverse events have been defined to include any adverse experience that results in any of the following outcomes:

- Death
- A life-threatening adverse experience
- Overdose to any medication
- Inpatient hospitalization or prolongation of existing hospitalization
- A permanent or severe disability
- A congenital anomaly/birth defect
- Important medical events that do not result in death, are not life-threatening, and/or do not require hospitalization will be considered as serious if, based on appropriate medical judgment, they jeopardize the participant and would require medical or surgical intervention to prevent a serious adverse event.

# 8.2. Eliciting and Recording Serious Adverse Events

Reporting of serious adverse events will be accomplished by collecting information on these adverse experiences during annual, semi-annual and interim follow-up visits. In order to avoid bias in eliciting serious adverse events, these adverse events will be assessed using a standardized checklist based on study outcomes and total body system assessment.

For all participants, serious adverse events will be assessed semi-annually at the clinic, as well as collected during the interim, as reported. Serious adverse events will be reported to the Coordinating Center as they occur through routine data entry (within 2-3 days), with the exception of death or other life threatening and unexpected adverse events. All deaths or other life threatening and unexpected adverse of intervention assignment, must be reported to the Coordinating Center within 24 hours of clinic notification.

For participants assigned to the metformin treatment group, the NIH-NIDDK must provide a written report of all serious and unexpected adverse events to the Food and Drug Administration (FDA) in their annual IND report. If the event is a death/SAE, unexpected, and associated with the use of the DPPOS study drug (IND-approved metformin) as determined by the DPPOS medical monitor, the FDA must be notified by phone or fax within seven calendar days, followed by the written report within fifteen days.

All serious adverse events will be reported to IRBs by the local clinic following individual institutional guidelines.

# 9. DATA PROCESSING

# 9.1.Data Forms

DPPOS data forms are completed to document protocol performance and to collect participant data relevant to the research questions. The section that follows outlines each type of data form that is used to collect participant data and is contained in the master database maintained by the Coordinating Center (CoC). Chapter 12 is the schedule of outcomes collection. The list of DPPOS data forms appears in the study Manual of Operations, and includes administrative as well as data collection instruments.

The CoC creates the DPPOS data form templates. At each clinic, the clinic staff, directed by the program coordinator, reviews completed data forms prior to data entry. Completed forms are edited as they are entered into the data management system, and then again via the central data management system at the CoC.

# • Follow-up visit inventories:

Completed semi-annually: serious adverse event assessment, diabetes management, current concomitant prescription medications, interval history and interval cardiovascular history, and physical measures (mid-year through year 12); and for the metformin treatment participants, pregnancy questions, and medication compliance and dispensing. In addition,

- at each annual visit: neuropathy screening and neuropathic history.
- o at each mid-year visit through year 12: Beck depression scale,.
- during year 5: retinal photography, ankle brachial index, SF-36 questionnaire, nutrient intake, and selected biochemical markers
- during year 8: physical functioning, cognition questionnaires, Quality of Well Being, and SF-36 questionnaire
- during year 10: Quality of Well Being, resource utilization, SF-36 questionnaire, physical functioning, cognition questionnaires, ankle brachial index, coronary artery calcium
- during year 11: selected biochemical markers, nutrient intake, cancer history and risk factor questionnaire, retinal photography
- o during year 12: Quality of Well Being, SF-36 questionnaire
- during year 13: Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)

#### • Interim follow-up visit inventory:

Reason for interim visit, serious adverse event assessment, interval history, pregnancy questions, and for metformin treatment participants, medication compliance and dispensing.

# • Missed follow-up visit report: Completed anytime a participant misses a scheduled follow-up visit: reason for missed visit and inactive follow-up status.

# • Home visit report

Completed for outcome visits: serious adverse event assessment, interval history, current concomitant prescription medications, and physical measures (as

appropriate); and for the metformin treatment participants, pregnancy questions, and medication compliance and dispensing.

The following data forms are completed to collect information on lifestyle sessions:

# • Group Session Log:

Completed for each GLS or BLS group session. Includes type of session and participants.

# 9.1.1. Other Forms

The following instruments are completed according to the schedule in Chapter 12:

- Beck Questionnaire
- MOS SF-36 Health Survey Questionnaire
- Modifiable Activity Questionnaire
- Nutrition Interview
- Resource utilization for participants
- Interval History Questionnaire
- Quality of Well-Being Scale
- Urinary Incontinence Questionnaire
- Neuropathy Questionnaire
- Dietary Restraint, Exercise Self-Efficacy, Low Fat Diet Self-Efficacy
- Cognition questionnaires
- Physical functioning: Grip strength, Gait Speed, Chair Stand, Balance
- Cancer history and risk factor questionnaire
- Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)

The following event data forms are completed as needed:

- Adverse event reports
- Diabetes confirmation report
- Pregnancy confirmation and outcomes reports
- Mortality report

The following procedure worksheets collect participant status or physical information (see Section 12 for frequency of procedures):

- OGTT procedures
- Urine collection procedures
- ECG procedures
- Fundus photo procedures
- Coronary artery calcium procedures
- DEXA procedures

The following report data forms are completed as needed:

The Biostatistics Center, George Washington University Rockville, Maryland

- CHD Risk Status Report
- Consent and specimen status

# 9.2.Data Entry and Management System

#### 9.2.1. Clinical Centers

A secure, web-based password protected data entry and management software corresponding to the data forms completed at a clinical center is developed and maintained by the staff at the Coordinating Center (CoC). Reports are developed for use at the clinical centers to assist clinical center staff in data collection and study management. DPPOS computers provided by the CoC are kept in a safe location in a site that is locked when not attended.

# 9.2.2. Central Biochemistry Laboratory

The Central Biochemistry Laboratory (CBL) uses a relational database to manage analyses performed within the laboratory using a custom-developed Laboratory Information Management System (LIMS). Automated analyzers are connected to the database via communication interfaces developed and maintained by the CBL staff. Reports to the CoC are transmitted via secure FTP to the CoC with the original reports stored in the relational database as well as on a file server. All storage media containing clinical data in use at the laboratory utilize hardware fault redundancy and the data are backed up daily to a secure and remote data storage facility.

#### 9.3.Centralized Data Management System

Data entered via the web-based electronic data collection system is securely transmitted over the Internet and stored on the CoC's server. Data are converted to SAS data sets after being uploaded to the CoC's server. All new data are edited for unavailable, out of range, or inconsistent values. Weekly audit programs produce more detailed edits across forms for an individual participant. Summaries are prepared for reports to the Steering Committee. The CoC maintains confidentiality of patient data and emerging results per a confidentiality policy, which every staff member is required to sign annually.

The CoC adheres to the Biostatistics Center's data backup and security policies to ensure the safety and confidentiality of the data. Backup procedures include: twice-weekly system backup, daily incremental backup, and off-site disaster recovery backup. Security procedures include: logon and link password protection, and for internet access, separate Web servers which use SSL and encryption algorithms. Virus and malware protection software is used on all computers and is updated on an hourly basis. All portable computers employ full disk encryption. University computing facilities provide support in the event of a disaster. Access to the server and databases is secured by use of login user accounts and passwords. Remote access is granted only to authorized users and is accomplished using a secure virtual private network (VPN). Appropriate filtering/firewall setup is used to prevent unauthorized access.

# 9.4.Performance Monitoring

# 9.4.1. Training Workshop and Site Visits

The CoC, Central Units, and the Lifestyle Resource Core (LRC), with appropriate investigator subcommittee members, will establish procedures to train and certify clinical investigators in the protocol, manual of operations, and data processing procedures. Workshops are held for training personnel from the clinical centers to address the appropriate DPPOS procedures including the use of the DPPOS data forms and data processing systems. CBL personnel will instruct the program coordinators on proper packaging and mailing of specimens for analysis by the CBL. Central units also instruct, train and certify the program coordinators and technicians (as needed) to promote standard assessments. The CoC and the LRC will maintain close contact with the program coordinators and will provide additional training or review as needed.

Based on clinic performance monitoring, appropriate representatives from the CoC, the LRC, the NIDDK, and clinic investigators will visit the clinical centers, as required. These site visits will review procedures with the program coordinators/technicians, assess proficiency in executing the DPPOS protocol, review deficiencies detected in monitoring the performance of the clinical centers, review the utilization of personnel relative to the amounts budgeted, and receive feedback on the adequacy of the centralized support operations.

#### 9.4.1.1 Periodic Performance Reports

During the DPPOS, the CoC will monitor the performance of the clinical centers and produce periodic reports summarizing protocol performance for the Protocol Oversight Program (POP) committee.

#### 9.4.1.2 Retention

The CoC and the POP will monitor the performance of the clinical centers in retaining participants. The CoC will also prepare monthly reports on participant compliance with the DPPOS protocol and participants on inactive follow-up.

#### 9.4.1.3 DPPOS Data Form Completion

The CoC will prepare periodic reports presenting tabulations for data completion and quality. Missing data, particularly on outcome variables, will effectively reduce the power of analyses. In fact, systematic patterns of missing data could bias the study results. Therefore, many of the procedural details outlined in the Manual of Operations are designed to minimize the amount of missing data.

# 9.4.1.4 Other Reports

Other reports will be developed, as needed, based on requests from the Steering Committee and associated subcommittees.

# **9.5.Interim Statistical Reports**

Interim reports to the Data and Safety Monitoring Board (DSMB) will include adverse events by treatment group, study progress, major issues considered and decided by the Steering Committee, protocol modifications, ancillary studies approved, protocol compliance, and data quality. Highlights of completed analyses related to study papers will be presented as they become available. There will be two formal interim analyses of safety and efficacy pertaining to macrovascular events for purposes of possible "early stopping" of an intervention.

# **10. STUDY ADMINISTRATION**

# 10.1. Organizational Units

# 10.1.1. Clinical Centers

Each of the participating clinical centers has agreed to implement the DPPOS Protocol. The clinical centers will follow participants according to protocol; assume responsibility for the completion of the protocol for each participant enrolled in the study; record participant data related to the above; review and enter information from data forms using the data entry and management system; and respond to edit queries from the Coordinating Center (CoC). Each clinical center has a Principal Investigator, a Program Coordinator, and additional staff to carry out the protocol.

# 10.1.2. Coordinating Center

The Coordinating Center (CoC) is responsible for all aspects of biostatistical design, analysis, data processing and study communications of the DPPOS. In collaboration with the Steering Committee, the CoC is responsible for editing and document processing of the protocol and Manual of Operations and data collection forms development and testing. The CoC provides protocol performance monitoring data, and conducts the interim and final statistical analyses. The CoC collaborates with the Steering Committee members in the preparation of publications based on study results.

Central resource units include the Central Biochemistry Laboratory (CBL), Nutrition Coding Center (NCC), ECG Grading Center (ECG), Fundus Photo Reading Center (FPRC), Quality of Well Being Coding Center (QWB), Coronary Artery Calcium Reading Center, Cognition Center, and DPPOS Central Genetics Core. Other than the Genetics Core and the Cognition Center, these units function as subcontracts to the CoC. Each is required to be in compliance with its IRB and institutional requirements for human subjects protection and HIPAA. They establish and provide baseline and/or repeated measures of study outcomes as described in Sections 5 and 12. Quality control systems are established for these centrally performed assessments and reports will be furnished periodically to the Research Group. In addition, the units will lend expertise to help formulate the protocol and detailed procedures for participant preparation, specimen and record labeling, handling and shipping. Secure communication systems are maintained for data transfer to the Coordinating Center.

#### 10.2. Funding Mechanism/Study Resources

The DPPOS is supported by the National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases, other co-funding NIH Institutes and Centers, and other DHHS co-funding Agencies. All support to the clinical centers and the Coordinating Center will be provided through the NIDDK using the mechanism of the Cooperative Agreement.

The NIDDK program officer will provide program involvement as a participant in the scientific efforts of the DPP Research Group through development of protocols and assistance in the conduct of the DPP.

# **10.3.** Working Committees

# 10.3.1. Steering Committee and Subcommittees

The Steering Committee (SC) is the representative body of the research group. The Committee consists of the Principal Investigator from each clinical center and the CoC, and the NIDDK Project Scientist. This committee is the policy and decision making group, and will oversee the administrative aspects of the DPPOS Research Group. It provides overall scientific direction through consideration of recommendations from the subcommittees and Executive Committee. The committee will approve the details of study design and all procedure manuals and participant management policies. The SC will monitor protocol adherence at the clinical centers including proper data generation, recording and transmittal. Members unable to attend a meeting may designate an alternate to act on their behalf. The members of the Steering Committee select the Study Chairperson and Vice-Chairperson.

Steering Committee recommendations for changes in the Protocol require prior consideration by the appropriate subcommittee or Planning Committee, and an affirmative vote by two-thirds of the Steering Committee members present and voting.

Although the Steering Committee is the decision and policy-making group of the DPPOS, a smaller group has been appointed to direct day-to-day activities. This Executive Committee consists of the Chair of the Steering Committee, the Vice-Chair of the Steering Committee, the Chair of the Publications and Presentations Committee, the NIDDK Project Scientist and Program Official, and the Principal Investigator and Project Coordinator of the CoC. The committee meets by telephone conference, as necessary, and generally on a weekly basis. Other members of the Steering Committee, such as chairs of Sub-Committees, are asked to attend the weekly conference call on a regular basis and as needed to address specific issues.

Subcommittees comprise members of the research group. Their function is to develop detailed policies and procedures and make recommendations to the Steering Committee. The following subcommittees are active during the start-up of the DPPOS. During DPPOS the subcommittees will be reformed and new subcommittees and working groups formed, as necessary to address different tasks and functions.

Initial DPPOS Subcommittees:

- Ancillary Studies
- Economic Evaluation Workgroup
- Outcomes Classification
- Program Coordinator
- Protocol Oversight Program
- Publications and Presentations
- Quality Control

# 10.3.2. Data Safety Monitoring Board

The Data and Safety Monitoring Board (DSMB) members will serve as external reviewers and advisors to the NIDDK-NIH and the Steering Committee. The DSMB will consist of experts in relevant biomedical fields, Biostatistics and medical ethics. Prior to the initiation of the DPPOS, the DSMB members will review the protocol and study material to ensure the scientific validity of the study and safety of participants. The DSMB will also assess the performance of the CoC and clinical centers. Its principal responsibility will be to monitor the emerging results to assess treatment effectiveness, or ineffectiveness, and participant safety. Based on these considerations, the DSMB may recommend to the NIDDK that the protocol be modified or that the study be terminated.

# 10.4. Policies

#### **10.4.1. Publications**

The Publications and Presentations Subcommittee (PPS) will coordinate, monitor, review, and assume responsibility for arranging the preparation of all study-wide communications (press releases, interviews, presentations, and publications) relating to the scientific aspects of the study. There will be no publication or presentation of study plans or results which have not been reviewed and approved by a majority of the PPS, and for some types of communications, a majority of the Steering Committee.

With respect to publications and presentations from the DPP, the goals of the PPS are to: 1. Ensure accurate, uniform, timely, and high quality reporting of the DPP activities and results;

- 2. Preserve the scientific integrity of the study;
- 3. Safeguard the rights and confidentiality of participants;

4. Assure that the timing of publications and presentations serves the right of the public to know the results of the program without jeopardizing its conduct.

The PPS will organize a writing group for each publication or presentation proposed by

the DPP investigators. Members of the writing group will include volunteers from the DPP investigators at large, and will not be restricted to members of the PPS. The PPS will coordinate the efforts of the writing group, establish priorities for data analysis by the Coordinating Center, and help edit the manuscripts produced by the writing groups.

There will be several categories of publications and presentations, with different rules for authorship, ranging from publications of the main results of the study (with authorship by the entire research group) to other types of publications with named authors. The authorship rules balance the need to recognize the contributions of all investigators and staff with the need to recognize individuals for specific contributions to certain types of publications and presentations. Detailed policies are found in the MOO.

# **10.4.2.** Ancillary Studies

The Ancillary Studies Subcommittee will evaluate all proposals for studies that involve DPPOS participants and that are not a part of the protocol. These studies will, in general, be done only on a subset of participants in the DPPOS. However, studies that include all participants and studies that analyze study data in ways extracurricular to the Protocol must also be submitted to the Ancillary Studies Subcommittee. Ancillary studies will have to obtain funding from outside the study.

Major factors in consideration of ancillary studies will include:

• Clinical importance and scientific validity

The Biostatistics Center, George Washington University Rockville, Maryland

- Compatibility of goals with those of DPPOS
- Amount of burden on study subjects and staff

Ancillary studies will receive a primary, secondary and statistical review. An outside reviewer may be used if there is no expertise within the study in a specific area. Reviews will be returned to the applicant and appeals from the decision of the Ancillary Studies Subcommittee may be made to the Steering Committee.

Approved ancillary studies will be reviewed by the DSMB. Detailed policies are found in the MOO.

# **11. STATISTICAL CONSIDERATIONS**

#### 11.1. Data Relevant to the Primary Outcome

After approximately 2.8 years of mean study time, the DPP's external Data and Safety Monitoring Board and sponsoring institute, the NIDDK, concluded that the DPP had convincingly demonstrated that the intensive lifestyle intervention and metformin therapy decreased the development of diabetes. Compared with placebo, intensive lifestyle and metformin reduced the development of diabetes by 58% and 31%, respectively. Both results were highly significant and lifestyle was significantly more effective than placebo (4). The therapies were effective across all ethnic and racial groups and in men and women. The intensive lifestyle intervention cohort achieved the target goal of 7% mean weight loss and at least 150 min of activity per week at year 1. The hazard rates for development of diabetes were: placebo 11.0, metformin 7.8, and lifestyle 4.8 per 100 person-years.

At the end of DPP, 99.6% of the study cohort was alive. The entire cohort proved to be remarkably compliant, with 94% retention of volunteers over time, and completion of > 90% of study requirements. Adherence (>80% of assigned medication) to metformin was 72%.

# 11.2. Study Power

The duration of follow-up in the first five years of DPPOS was extended by one year from 5 to 6 years, by NIDDK. Power calculations have been modified based on actual enrollment, and to correspond to the reordering of outcome measures.

The following assumptions were used to make revised estimates of the power of the DPPOS for the Phase 1 primary outcome, development of diabetes:

- The study will enroll approximately 900 participants per treatment group
- The Phase 1 primary outcome is time to the confirmed development of diabetes assessed through DPPOS Phase 1.
- Type I error rate (α) of 0.05 (two-sided) with a Bonferroni adjustment (99) for two pair-wise comparisons of the intervention groups vs. "control".
- Control (formerly placebo) group's time to the development of diabetes is exponentially distributed with a diabetes development hazard rate of at least 0.066 per year.
- In the intervention groups (i.e., intensive lifestyle or metformin), the diabetes development hazard rate is reduced by at least 30%.
- 84% participation of DPP participants in the follow-up study and a dropout rate of not more than 2%/year.

For the comparison of lifestyle vs. control, assuming a type 1 error .025 and a 2-sided test, the study will have 84% power to detect a 35% reduction in the hazard rate for development of diabetes and 94% power to detect a 40% reduction. For the comparison of metformin vs. control (type 1 error .025, 2 sided test), the study will have 82% power to detect a 35% reduction in hazards.

For the composite primary microangiopathic outcome at year 11, assuming N=850 remaining participants per group and 1% per year dropout, and applying the resulting numbers of participants expected to develop diabetes during the follow-up study, we estimate the power of the study to be 91 percent or greater to detect 25% or greater reductions for each intervention

from the control group proportion with the microangiopathic outcome, and 74% power to detect 20% reductions, using 2-sided pair-wise comparisons vs. placebo with  $\alpha = 0.025$ .

#### 11.3. Analysis

#### 11.3.1. Analysis of Development of Diabetes

The primary objective for the first Phase of the DPPOS study is to compare the durability of the original effect during the DPP, i.e., estimation of the hazard rates for development of diabetes *going forward* among participants who did not develop diabetes during DPP among those who enrolled into DPPOS. The analysis will be based on comparing the hazard rates between the two intervention groups (the former Intensive Lifestyle and Metformin groups) and the former placebo group. The primary null hypothesis is that among those who had not developed diabetes by the start of DPPOS, the intervention groups do not differ from the controls in the hazard rates for development of diabetes over the interval from the beginning of the longterm follow-up study. Reasons for comparing across the interval from the start of the long-term follow-up study as the primary analysis rather than from the beginning of DPP are: 1) we will have already published the comparison of the three groups over the DPP interval, and any subsequent comparison encompassing that interval would not be an independent analysis; and 2) if the interventions are indeed effective over the earlier DPP interval, the cumulative incidence curves may have too much separation from the early DPP effects to be able come together again, even if the interventions are not effective over the longer term. The primary analysis from DPPOS baseline does not preclude secondary analyses from the beginning of DPP.

The cohort of participants for this analysis are a subset of the original DPP study population, and as such are no longer "randomized", but rather selected by having survived DPP without developing diabetes. Beyond that selection, each participant will be included in the group to which s/he was randomly assigned, regardless of compliance with study treatment. The number of participants who had not developed diabetes at DPP study end was 870 in the metformin group, 951 in the ILS, and 809 in the placebo group. The primary outcome analysis will use an overall significance level of  $\alpha = 0.05$  (2-sided). Two pair-wise comparisons between the intervention groups and the former placebo group, set at the  $\alpha = 0.025$  level, will be performed if the overall comparison is statistically significant.

The analysis will compare the treatment groups vs. the former placebo group on DPP baseline characteristics, and any factors on which they differ will be considered for inclusion as covariates in the analysis. The primary analysis will be a life-table analysis of the time to confirmed development of diabetes. Modified product-limit life-table estimated cumulative incidence curves will be calculated for each treatment group and the groups compared using a log rank test (102). Participants will be considered "administratively censored" if they complete the full duration of follow-up without confirmed development of diabetes. Participants who prematurely discontinue their follow-up visits prior to confirmed development of diabetes will be used to evaluate potential covariates that may modify the time to development of diabetes. Graphical procedures will be used to assess the proportionality assumption. If the proportionality assumption is found to be unreasonable then other models such as the accelerated failure time model (103, 104) or the proportional odds model (105) will be used to evaluate the covariates.

Mortality prior to the development of diabetes may be a competing risk event for the primary outcome (106, 107). To account for mortality as a competing risk event, the treatment groups will be compared on the composite event defined as confirmed development of diabetes or all-cause mortality, whichever occurs first, using the same methods described above for the primary outcome. The analysis will also be conducted within subgroups (one-way stratification) based on the following characteristics: racial/ethnic origin, gender, and age (<60, 60+).

The primary analyses that focus on the intention-to-treat assignment during DPP will include all participants in the original DPP placebo, lifestyle and metformin intervention groups who have enrolled in DPPOS. Since the participants originally assigned to troglitazone only had a limited exposure to that intervention, owing to the premature termination of the troglitazone arm, and were not included in the primary DPP outcome analyses, they will not be included in the primary DPPOS analyses.

# 11.3.2. Composite Outcomes of Microangiopathic, Neuropathic and Cardiovascular Disease

The analysis of the composite primary microangiopathic outcome at year 11, and composite secondary cardiovascular disease outcome will be performed in an intent-to-treat fashion on the DPP groups, as randomized, including participants who have developed diabetes.

For both composite outcomes, the objective is to determine the effect of the interventions on the proportion of participants experiencing the outcome through follow-up visit year 11. For the composite primary microangiopathic outcome, the groups will be compared using the global test using general estimating equations (GEE) among DPPOS enrolled participants. The year 11 data for each component will be reviewed with respect to being "missing at random" before selecting the appropriate statistical methods for missing data.

For the composite secondary cardiovascular outcome, the groups will be compared on the time to event from DPP randomization through DPPOS year 11 using all participants randomized into DPP.

#### 11.3.3. Secondary Research Questions

Secondary objectives of the post-DPP study are to evaluate the long-term effects of DPP interventions on selected individual health outcomes. These are:

- Further development of diabetes
- Diabetic retinopathy
- Diabetic neuropathy
- Albuminuria
- Renal failure
- Macrovascular disease
- Cardiovascular disease events
- Subclinical atherosclerosis outcomes
- Risk factors for cardiovascular disease
- Amputation in a lower extremity not resulting from major trauma
- Hospitalizations
- Physical activity, nutrition, body mass and obesity
- Dietary and exercise behaviors

The Biostatistics Center, George Washington University Rockville, Maryland

- Physical functioning
- Quality of life indices
- Health care costs
- Cognitive performance
- Urinary incontinence
- Cancer incidence

<u>Other Analyses</u>. Other research questions will examine the clinical course of IGT and newly diagnosed diabetes with regard to the development of microvascular, neuropathic and cardiovascular disease and their respective risk factors. These "epidemiologic" analyses will largely be descriptive. Appropriate statistical methods will be applied to analyze the interactions among putative and established risk factors and the development of different outcomes. In these analyses, treatment assignment during the DPP will be considered a covariate.

The former troglitazone participants who continue in the DPPOS through visit year 6 will be included in the "other" outcomes exploring the relationship between incident diabetes and determinants of long-term complications of new-onset diabetes and IGT. No research data will be collected in this group beginning with protocol version 3.0.

# 11.4. Monitoring

An external Data and Safety Monitoring Board will review reports of study progress and safety regularly throughout the study. They will alert the NIDDK and the Steering Committee if they believe the study should be stopped for reasons of patient safety.

Because we have already shown both interventions to be effective in delaying or preventing diabetes over 3 years, there would be no compelling reason to stop the follow-up study for having demonstrated further benefit. The assessment of the composite microangiopathy will occur after the year 11 visits. Therefore, we do not intend to implement a formal statistical monitoring plan for either of these outcomes. The DSMB will review two interim analyses of time to macrovascular event for safety.

# 12. OUTCOMES SCHEDULE Outcomes Schedule, Visit Years 1-6

Participant DPPOS visit year	Yea	ar 1	Ye	ear 2	Ye	ar 3	Year 4		Year 5		Year 6		
Visit calendar year	9/1/02-1	0/31/03	7/1/03-	10/31/04	7/1/04-1	10/31/05	7/1/05-1	0/31/06	7/1/06-10/31/07		7/1/07-10/31/08		
DPPOS funding calendar year	2/1/03-	1/31/04	2/1/04	-1/31/05	2/1/05-	1/31/06	2/1/06-2	2/1/06-1/31/07		2/1/07-1/31/08		2/1/08-1/31/09	
Mid-year or Annual visit	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	
Glycemia													
Fasting glucose	Х	Х	Х	Х	X	X	X	Х	Х	X	Х	X	
30', 120' glucose++		Х		X		X		X		X		X	
HbA1c ++		X		X		X		X		X		X	
Insulin Secretion and Sensitivity													
Fasting, 30' insulin++		Х		Х		X		Х		X		X	
Inflammatory, clotting and fibrinolytic factors													
Fibrinogen		X								X			
ТРА		Х								X			
CRP		X								X			
Lipids													
Lipid profile		X		X		X		X		X		X	
Particle size and sub fractions		Х								X			
Kidney Function													
Urine albumin & creatinine		Х		X		X		X		X		X	
Serum Cystatin		Х								X			
Serum Creatinine		X		X		X		X		X		X	
History													
Symptoms and Events	Х	X	X	X	X	X	X	X	X	X	X	X	
Physical													
Weight	X	Х	Х	X	X	X	X	Х	Х	Х	Х	X	
Height		Х								Х			
Waist Circumference		Х		Х		X		Х		X		X	

# **Outcomes Schedule, Visit Years 1-6, Continued**

Participant DPPOS visit year	Ye	ar 1	Ye	ar 2	Yea	ar 3	Year 4		Year 5		Year 6	
Visit calendar year	9/1/02-	10/31/03	7/1/03-1	10/31/04	7/1/04-1	10/31/05	7/1/05-10/31/06		7/1/06-10/31/07		7/1/07-10/31/08	
DPPOS funding calendar year	2/1/03	-1/31/04	2/1/04-	1/31/05	2/1/05-	1/31/06	2/1/06-1/31/07		2/1/07-1/31/08		2/1/08-1/31/09	
Mid-year or Annual visit	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann
Blood Pressure												
Arm BP	X	X	X	X	Х	Х	Х	Х	Х	X	Х	X
ABI		X								Х		
Quality of Life												
Beck	X		X		Х		Х		Х		X	
SF-36		X								Х		
Urinary Incontinence		X		X		Х		Х		Х		X
Physical Activity and Nutrition												
MAQ		Х		Х		Х		Х		Х		X
Nutrition Intake		X		Х						Х		
Cardiovascular												
ECG		X		Х		Х		Х		Х		X
Carotid Ultrasound+												
Eye												
Retinal photography#		X								Х		
Neurologic												
Symptom Assessment		X		Х		Х		Х		Х		X
MNSI with monofilament		Х		Х		Х		Х		Х		X
Heart rate variability		Х		Х		Х		Х		Х		X
Saved Specimens												
Fasting EDTA Plasma		X		Х		X		X		Х		X

#### **Outcomes Schedule, Visit Years 1-6, Continued**

Participant DPPOS visit year	Year 1		Year 2		Year 3		Year 4		Year 5		Year 6	
Visit calendar year	9/1/02-10/31/03		7/1/03-10/31/04		7/1/04-10/31/05		7/1/05-10/31/06		7/1/06-10/31/07		7/1/07-10/31/08	
DPPOS funding calendar year	2/1/03-	1/31/04	2/1/04-	1/31/05	2/1/05-2	1/31/06	2/1/06-	1/31/07	2/1/07-1/31/08		2/1/08-1/31/09	
Mid-year or Annual visit	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann
Safety Measures												
Serum creatinine		Х		Х		Х		Х		Х		Х
CBC*		Х		X		Х		Х		Х		X
Serious Adverse event report**	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	X
Pregnancy##		Х		X		Х		Х		Х		Х
Serology												
IA2***, GAD***												
Other Chemistries												
Relevant biological markers related to the pathogenesis of diabetes and its complications		Х								Х		
Economic Evaluation												
Resource Utilization								Х				
QWB		Х		X		Х		Х		Х		X

# Fundus photos were obtained in Year 1 or 2 on a subset of diabetic and non-diabetic participants. Year 5 photos were completed on all participants in the former lifestyle, metformin and placebo arms.

## Pregnancy tests as needed for participants on metformin based on symptoms and menstrual history and measured locally.

\* In the Metformin treatment group on study metformin measured locally.

\*\* Serious Adverse events will be collected at Annual, Mid-year and Interim follow-up visits.

\*\*\* Specimen for IA2 and GAD antibodies will be collected at the time of confirmation and will be analyzed for those who converted.

+ Carotid ultrasounds were collected during the DPP bridge period as a baseline for DPPOS

++ For diabetic participants: HbA1c is collected at Mid-Year visits; the 30' insulin and 30/120' glucose collections are discontinued

+++ The following outcomes are not obtained for participants in the former troglitazone arm: carotid ultrasound, fundus photographs, other chemistries

# **Outcomes Schedule – Visit Years 7-12**

Participant DPPOS visit year	Ye	ar 7	Ye	ar 8	Yea	ar 9	Yea	r 10	Yea	ır 11	Yea	r 12
Visit calendar year	9/1/08-2	10/31/09	7/1/09-1	10/31/10	7/1/10-1	10/31/11	7/1/11-1	10/31/12	7/1/12-2	10/31/13	7/1/13-1	10/31/14
DPPOS funding calendar year	2/1/09-	1/31/10	2/1/10-	1/31/11	2/1/11-	1/31/12	2/1/12-	1/31/13	2/1/13-	1/31/14	2/1/14-	1/31/15
Mid-year or Annual visit	Mid	Ann										
Glycemia												
Fasting glucose	X	X	X	X	Х	Х	Х	Х	X	X	X	X
30', 120' glucose+		X		X		X		Х		X		X
HbA1c +		X		X		X		Х		X		X
Insulin Secretion and Sensitivity												
Fasting, 30' insulin+		X		X		Х		Х		X		X
Inflammatory, clotting and fibrinolytic factors												
Fibrinogen										X		
ТРА										X		
CRP										Х		
Lipids												
Lipid profile		X		X		Х		Х		X		X
Particle size and subfractions										X		
Kidney Function												
Urine Albumin & Creatinine		X		X		Х		Х		X		X
Serum Cystatin				X		X		Х		X		X
Serum Creatinine		X		X		Х		Х		X		X
History												
Symptoms and Events	Х	X	X	X	Х	Х	Х	Х	X	X	X	X
Cancer History and Risk Factors										X		
Physical												
Weight	Х	X	X	X	Х	Х	Х	Х	X	X	X	X
Height										X		
Waist Circumference		X		X		X		X		X		X
DEXA (body composition measures)+++												X

# **Outcomes Schedule – Visit Years 7-12, Continued**

Participant DPPOS visit year	Ye	ar 7	Yea	ar 8	Ye	ar 9	Yea	r 10	Yea	ır 11	Yea	r 12	
Visit calendar year	9/1/08-	10/31/09	7/1/09-1	0/31/10	7/1/10-2	10/31/11	7/1/11-1	10/31/12	7/1/12-1	10/31/13	7/1/13-1	10/31/14	
DPPOS funding calendar year	2/1/09-	-1/31/10	2/1/10-	1/31/11	2/1/11-	1/31/12	2/1/12-	2/1/12-1/31/13		2/1/13-1/31/14		2/1/14-1/31/15	
Mid-year or Annual visit	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	
Blood Pressure													
Arm BP	X	X	X	X	Х	X	Х	Х	X	X	X	X	
ABI ++								Х					
Quality of Life													
Beck	Х		X		Х		Х		X		X		
SF-36			X				X		X		X		
Urinary Incontinence		X		X		X		Х		Х		X	
Physical Activity, Nutrition, Behavior, Functional													
MAQ		X	X		Х		Х		X		X		
Nutrition Intake										X			
Dietary Restraint, Exercise Self-Efficacy, Low Fat Diet Self-Efficacy			X		Х		X		X		X		
Physical Function tests (Grip strength, CES-D Depression, Gait Speed, Chair Stand, Balance)			X				Х						
Cognition													
Cognitive Function tests			X				Х						
Cardiovascular													
ECG		X		X		X		Х		Х		X	
Coronary Artery Calcium ++								Х					
Eye													
Retinal Photography ++										Х			
Neurologic													
Symptom Assessment		X		X		X		Х		X		X	
Modified MNSI including monofilament		X		X		X		Х		Х		Х	
Heart rate variability		X		Х		X		Х		X		Х	

# **Outcomes Schedule – Visit Years 7-12, Continued**

Participant DPPOS visit year	Year 7		Year 8		Year 9		Year 10		Year 11		Year 12	
Visit calendar year	9/1/08-10/31/09		7/1/09-10/31/10		7/1/10-10/31/11		7/1/11-10/31/12		7/1/12-10/31/13		7/1/13-10/31/14	
DPPOS funding calendar year	2/1/09	-1/31/10	2/1/10-	1/31/11	2/1/11-	1/31/12	2/1/12-	1/31/13	2/1/13-1/31/14		2/1/14-1/31/15	
Mid-year or Annual visit	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann	Mid	Ann
Saved Specimens												
Fasting EDTA Plasma (no serum is stored)		X		X		Х		Х		Х		X
Safety Measures												
Serum creatinine		Х		X		Х		Х		Х		X
CBC*		Х		X		X		Х		Х		Х
Serious Adverse event report**	X	Х	X	X	Х	X	Х	Х	Х	Х	Х	X
Pregnancy##		X		X		Х		Х		Х		X
Other Chemistries												
Relevant biological markers related to the pathogenesis of diabetes and its complications										Х		
Economic Evaluation												
Resource Utilization								X				
QWB		X	X				X				X	

EOS = end of study

# Pregnancy tests as needed for participants on metformin based on symptoms and menstrual history and measured locally.

\* Collected from participant of the metformin treatment group on study metformin measured locally.

\*\* Serious Adverse events will be collected at Annual, Mid-year and Interim follow-up visits.

\*\*\* Specimen for IA2 and GAD antibodies will be collected at the time of confirmation and will be analyzed for those who converted.

+ For diabetic participants: HbA1c is collected at Mid-Year visits; the 30' insulin and 30/120' glucose collections are discontinued

++ The following will be completed at study end: ABI, retinal photography, coronary artery calcium

+++ DEXA scans will be completed on a sample of participants during DPPOS Year 12

Participant DPPOS visit year	Year 13			
Visit calendar year	7/1/14-3	10/31/15		
DPPOS funding calendar year	2/1/14-	1/31/15		
Mid-year or Annual visit	Mid	Ann		
Glycemia				
Fasting glucose		X		
HbA1c		X		
Insulin Secretion and Sensitivity				
Fasting		X		
Kidney Function				
Urine Albumin & Creatinine		X		
Serum Cystatin				
Serum Creatinine		X		
History				
Symptoms and Events including CVD and Cancer)	Х	X		
Cancer Risk Factors		X		
Physical				
Weight		X		
Waist Circumference		X		
Blood Pressure				
Arm BP		X		
Physical Activity, Nutrition, Behavior, Functional				
ADL/IADL		X		
Neurologic				
MNSI		X		
Monofilament		X		
Saved Specimens				
Fasting Serum and EDTA Plasma		X		
Spot Urine		X		
Additional Safety Measures				
CBC*		X		
Serious Adverse Event report**	X	X		
Pregnancy#		X		

#### **Outcomes Schedule – Visit Year 13**

# Pregnancy tests as needed for participants on metformin based on symptoms and menstrual history and measured locally.

\* Collected from participant of the metformin treatment group on study metformin measured locally.

\*\* Serious Adverse events will be collected at Annual, Mid-year and Interim follow-up visits.

# 12.1. Visit Schedule

Annual visits will be targeted for the anniversary of the participant's original DPP randomization date. Mid-year visits will take place 6 months before and after annual visits.

# **13. STUDY TIMETABLE**

# **Diabetes Prevention Program**

Phase I	July 1994 – June 1996	Protocol Development and Implementation				
	July 1994 – December 1995	Protocol Development				
	January 1996 – June 1996	Protocol Implementation				
Phase II	July 1996 – June 2002	Participant Randomization and Follow-up				
	July 1996 – June 1999	Recruitment and Follow-up				
	July 1999 – December 2001	Participant Follow-up				
Phase III	June 2001	Initiate Study Close-out and Data Analysis				
Phase IV	January 1, 2002	Bridge Period Starts				
	August 31, 2002	Bridge Period Ends				

# **Diabetes Prevention Program Outcomes Study**

Planning	January 2002 – August 31, 2002	Protocol development
Phase I	September 1, 2002 – January 31, 2009	Participant follow-up
	July 2006 – October, 2007	Year 5 major visit
	February 1, 2008 – January 31, 2009	Phase I Analysis
	June 2008	Submit funding renewal
Phase II	February 1, 2009 – October 2015	Participant follow-up
	July 2012 – October 2013	Year 11 major visit
	October 2013	Begin Phase II Analysis
	May 2014	Submit funding renewal
	January 31, 2015	Current DPPOS funding ends

The Biostatistics Center, George Washington University Rockville, Maryland
## **14. BIBLIOGRAPHY**

- 1. Pan W. Sample size and power Calculations with Correlated Binary Data. Controlled Clinical Trials 2001;22:211-227.
- 2. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes mellitus. Diabetes Care 1999; 22:623-34.
- 3. Diabetes Prevention Research Group. Diabetes Prevention Program. Baseline characteristics of the randomized cohort. Diabetes Care 2000; 23:1619-29.
- 4. DPP Research Group. The Diabetes Prevention Program: Lifestyle modification and metformin reduce the incidence of type 2 diabetes mellitus. N Engl J Med 2002; 346:393-403.
- 5. ADA Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-97.
- 6. Harris MI, Goldstein DE, Flegal KM, Little RR, Cowie CC, Wiedmeyer H-M, Eberhard MS, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 1988; 21:518-524.
- 7. Rubin RJ, Altman WM, Mendelson DN. Healthcare expenditures for people with diabetes mellitus. JCEM 1994; 78:809A-09F.
- 8. Edelstein S, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997; 46:701-10.
- 9. Svetkey LP et al. Effects of dietary patterns on blood pressure. Subgroup analysis of the dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med 1999; 159:285-293.
- EDIC Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342:381-9.
- Wingard DL, Barrett-Connor E. Heart disease and diabetes. In Diabetes in America, 2nd ed. M Harris, ed. National Diabetes Data Group, NIH Pub No 95-1468, 1995.
- 12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
- 13. Pan WH, Cedres LB, Kiu K, et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiology 1986; 123:504-16.
- 14. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in Type 2 diabetes mellitus: how sweet it is ... or is it? Lancet 1997; 350(suppl 1):4-9.

- 15. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in Type 2 diabetes subjects. Diabetes Care 1993; 16:621-29.
- 16. Giugliano D, DeRosa N, DiMaro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16:1387-90.
- 17. UKPDS Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.
- 18. Bourn DM, Mann JI, McSkimming BJ, et al. Impaired glucose tolerance and type 2 diabetes: Does a life style intervention program have an effect? Diabetes Care 1994; 17:1311-19.
- 19. Torjesen PA, Birkeland KI, Andersen SA, et al. Lifestyle changes may reverse development of the insulin resistance syndrome. Diabetes Care 1997; 20:26-31.
- 20. Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343:16-22.
- 21. Paffenbarger RS, Wing AL, Hyde RT. Physical activity as an index of heart attack risk in college alumni. Am J Epidemiology 1978; 108:161-75.
- 22. Ekelund LG, Haskell WL, Johnson JL, et al. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men: the Lipid Research Clinics Mortality Follow-up Study. N Engl J Med 1988; 319:1379-84.
- 23. Javitt JC, Chiang Y-P. Economic impact of diabetes. . In Diabetes in America, 2nd ed. M Harris, ed. National Diabetes Data Group, NIH Pub No 95-1468, 1995.
- 24. The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care 2003; 26:36-47. PMCID: PMC1402339.
- 25. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360- 81.
- 26. Canner PL, Berge KG, Wenger NK, et al for the Coronary Drug Research Group. Fifteen-year mortality in coronary drug project patients: long-term benefits with niacin. J Am Coll Cardiol 1986; 8:1244-45.
- 27. Scandinavian Simvistatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvistatin Survival Study (4S). Lancet 1994; 344:1383-89.
- 28. Meigs JB, Nathan DM, Wilson PWF, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Int Med 1998; 128:524-33.
- 29. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283:221-28.

- 30. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes. JAMA 1990; 263:2893-8.
- 31. Jarret RJ, McCartney P, Keen H. The Bedford Survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982; 22:79-84.
- 32. Stengard JH, Tuomilehto J, Pekkanen J, et al. Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: the Finnish cohorts of the Seven Countries Study. Diabetologia 1992; 35:760-65.
- 33. Shaw JE, Hodge AM, De Courten M, Chitson P, Zimmet PZ. Isolated postchallenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999; 42:1050-1054.
- 34. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). Consequences of the new diagnostic criteria for diabetes in older men and women. Diabetes Care 1999; 22:1667-1671.
- 35. Barret-Connor E, Ferrara A. Isolated post challenge hyperglycaemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study. Diabetes Care 1998; 21:1236-1239.
- 36. Khaw KT, Wareham N, Luben R, Bringham S, Oakes S, Welch A, Day N. Glycated haemoglobin, diabetes and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 322:1-6.
- The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354:617-621.
- 38. Temelkoca-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23:1830-1834.
- 39. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl. J. Med 2000; 342:145-153.
- 40. Hansson L, Lindholm LH, Niskanen L, LAnke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, deFaire U, Morlin C, Karlberg BE, Wester PO, Bjorck J-E, for the Captopril Prevention Project (CAPPP) Study Group. Effect of Angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353:611-616.

- 41. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102:527-32.
- 42. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of Type 2 diabetes occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15:815-19.
- 43. Hamman RF, Mayer EJ, Moo-Young GA, et al. Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with Type 2 diabetes. San Luis Valley Diabetes Study. Diabetes 1989; 38:1231-37.
- 44. Haffner SM, Fong D, Stern MP, et al. Diabetic retinopathy in Mexican Americans and non-Hispanic whites. Diabetes 1988; 37:878-84.
- 45. Nagi DK, Pettitt DJ, Bennett PH, Klein R, Knowler WC. Diabetic retinopathy assessed by fundus photography in Pima Indians with impaired glucose tolerance and Type 2 diabetes. Diabetic Medicine 1997; 14:449-56.
- 46. Klein R, Barrett-Connor EL, Blunt BA, Wingard DL. Visual impairment and retinopathy in people with normal glucose tolerance, impaired glucose tolerance, and newly diagnosed Type 2 diabetes. Diabetes Care 1991; 14:914-18.
- 47. Jarrett RJ, Keen H. Hyperglycemia and diabetes mellitus. Lancet 1976; 2:1009-12.
- 48. Nathan DM, Singer DE, Godine JE, et al. Retinopathy in older type II diabetics: association with glucose control. Diabetes 1986; 35:797-801.
- 49. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988; 260:2864-71.
- 50. DCCT Research Group. The relationship of glycemic exposure to the risk of developing retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-83, 1995.
- 51. Stratton IM, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of Type 2 diabetes (UKDPP-OS 35): prospective observational study. BMJ 2000; 321:405-12.
- 52. Mykkanen L, Haffner SM Kuusisto J, Pyorala K, Laakso M. Microalbuminuria precedes development of Type 2 diabetes. Diabetes 1994; 43:552-57.
- Niskanen L, Penttila I, Parviainen M, Uusitpa M. Evolution, Risk Factors, and Prognostic Implications of Albuminuria in NIDDM. Diabetes Care 1996; 19:486-492
- 54. Forsblom CM, Eriksson JG, Ekstrand AV, Teppo AM, Taskinen MR, Groop LC. Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia 1995; 38:363-369.
- 55. Collins VR, Dowse GK, Finch CF, Zimmet PZ, Linnane W. Prevalence and risk factors for micro- and microalbuminuria in diabetic subjects and entire population of Nauru. Diabetes 1989; 38:1602-1610.

The Biostatistics Center, George Washington University Rockville, Maryland

- 56. Voutilainen-Kaunisto RM, Terasvirts ME, Uusitupa MI, Niskanen LK. Occurrence and predictors of retinopathy and visual acuity in type 2 diabetic patients and control subjects. 10-year follow-up from the diagnosis. J Diabetes Complications 2001; 15:24-33.
- 57. Fujikawa R, Okubo M, Egusa G, Kohno N. Insulin resistance precedes the appearance of albuminuria in non-diabetic subjects: 6 years follow up study. Diabetes Res Clin Pract 2001; 53:99-106.
- 58. Uusitupa M, Siitonen O, Penttila I, Ayo, A, Pyorala K. Proteinuria in newly diagnosed type II diabetic patients. Diabetes Care 1987; 10:191-194.
- 59. Standl E, Stiegler H. Microalbuminuria in a random cohort of recently diagnosed type 2 (non-insulin-dependent) diabetic patients living in the Greater Munich Area. Diabetologia 1993; 36:1017-1020.
- 60. Olivarius N de F. Andreasen AH, Keiding N, Mogensen CE. Epidemiology of renal involvement in newly diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes Care in General Practice", Denmark. Diabetologia 1993; 36:1007-1016.
- 61. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Hyperinsulinemic Microalbuminuria. Circulation 1995; 91:831-837.
- 62. Mykkanen L, Zaccaro L, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects. Diabetes 1998; 47:793-800.
- 63. Guizar JM, Kornhauser C, Malacara JM, Amador N, Barrera JA, Esparza R. Renal functional reserve in patients with recently diagnosed type 2 diabetes mellitus with and without microalbuminuria. Nephron 2001; 87:223-230.
- 64. Haffner SM, Stern MP, Gruber MK, et al. Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects: Arteriosclerosis 1990; 10:727-31.
- 65. Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF. Sensory neuropathy in non-insulin-dependent diabetes mellitus. Am J Epidemiol 1990; 1:633-643.
- 66. Ratzmann KP, Raschke M, Gander I, Schimke E. Prevalence of peripheral and autonomic neuropathy in newly diagnosed type II (noninsulin-dependent) diabetes. J Diabet Complications 1991; 5:1-5.
- 67. Sosenko JM, Kato M, Soto R, Goldberg RB. Sensory function at diagnosis and in early stages of NIDDM in patients detected through screening. Diabetes Care 1992; 15:847-852.
- Lehtinen JM, Niskanen L, Hyvonen K, Siitonen O, Uusitupa. Nerve function and its determinants in patients with newly-diagnosed Type 2 (non-insulin-dependent diabetes mellitus and in control subjects – a 5-year follow-up. Diabetologia 1993; 36:68-72.

- 69. Eriksson KF, Nilsson H, Lindgarde F, Osterlin S, Dahlin LB, Lilja B, Rosen I, Sundkvist G. Diabetes mellitus but not impaired glucose tolerance is associated with dysfunction in peripheral nerves. Diabet Med 1994; 11:279-285.
- 70. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Sittonen O, Uusitipa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. New Engl J Med 1995; 333:89-94.
- 71. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122:561-568.
- Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996; 124:90-96.
- 73. De Neeling JN, Beks PJ, Bertelsmann FW, Heine RJ, Bouter LM. Peripheral somatic nerve function in relation to glucose tolerance in an elderly Caucasian population: the Hoorn study. Diabet Med 1996; 13:960-966.
- Toyry JP, Niskanen LK, Mantysaari MJ, Lansimies EA, Uusitupa MI.
  Occurrence, predictors and clinical significance of automatic neuropathy in NIDDM. Ten-year Follow-up from the diagnosis. Diabetes 1995; 45:308-315.
- 75. Sands ML, Shetterly SM, Franklin GM, Hamman RF. Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1997; 20:322-329.
- 76. Fedele D, Como G, Cucinotta D, Feldman EL, Ghirlanda G, Greene DA, Negrin P, Santeusanio F. A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee. Diabetes Care 1997; 20:836-843.
- 77. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997; 20:S19-S25.
- 78. Sell DR, Nagaraj RH, Grandhee, SK, Odetti P, Lapolla A, et al. Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia. Diabetes/Metabolism Reviews 1991; 7:239-51.
- 79. Will JC, Strauss KF, Mendlein JM, et al. Diabetes mellitus among Navajo Indians: Findings from the Navajo Health and Nutrition Survey. J Nutr 127:2106S-2111S, 1997.
- Ghodes D. Diabetes in North American Indians and Alaska Natives. In: National Diabetes Data Group. Diabetes in America: Washington DC: 2nd edition, 1995 (NIH Publication No. 95-1468).
- 81. Flegal KM, Ezzati TM, Harris MI, et al. Prevalence of diabetes in Mexican Americans, Cubans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey, 1982-1984. Diabetes Care 1991; 14:628-638.
- 82. Burke JP, Williams K, Gaskill SP, et al. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: Results from the San Antonio Heart Study. Arch Intern Med 1999; 159:1450-1456.

The Biostatistics Center, George Washington University Rockville, Maryland

- 83. Carter JS, Pugh JA, Monterrosa A. Noninsulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med 1996; 125:221-232.
- 84. Osei K, Gaillard T, Schuster DP. Pathogenetic mechanisms of impaired glucose tolerance and type II diabetes in African-Americans: The significance of insulin secretion, insulin sensitivity, and glucose effectiveness. Diabetes Care 1997; 20:396-404.
- 85. Harris EL, Robinson CR, Georgopoulos A. Black-white differences in the risk of developing retinopathy among individuals with type 2 diabetes. Diabetes Care 1999; 22:779-783.
- 86. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med 1991; 325:1412-1417.
- Tull ES, Roseman JM. Diabetes in African Americans. In: National Diabetes Data Group. Diabetes in America: Washington DC: 2nd edition, 1995 (NIH Publication No. 95-1468).
- Cowie CC, Port FK, Wolfe RA, et al. Disparities in incidence of diabetic endstage renal disease according to race and type of diabetes. N Engl J Med 1989; 321:1074-1079.
- 89. Hamman RF, Franklin GM, Mayer EJ, Marshall SM, Marshall JA, Baxter J, Kahn LB. Microvascular complications of non-insulin dependent diabetes mellitus (Type 2 diabetes) in Hispanics and non-Hispanic whites: The San Luis Valley Diabetes Study. Diabetes Care 1991; 14 (Suppl. 3):655-664.
- 90. Tudor SM, Hamman RF, Baron A, Johnson DW, Shetterly SM. Incidence and progression of diabetic retinopathy in Hispanics and non-Hispanic whites with type 2 diabetes. San Luis Valley Diabetes Study, Colorado. Diabetes Care 1998; 21:53-61.
- 91. Harris MI. Non-insulin dependent diabetes mellitus in black and white Americans. Diabetes Metabolism Rev 1990; 6:71-90.
- 92. Mitchell BD, Hazuda HP, Haffner SM, Patterson JK, Stern MP. Myocardial infarction in Mexican Americans and non-Hispanic whites. The San Antonio Heart Study. Circulation 1991; 83:45-51.
- 93. Modan M, Halkin H. Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension. Diabetes Care 1991; 470-87.
- 94. American Diabetes Association, Treatment of Hypertension in Adults with Diabetes, Diabetes Care 2002; 25 (Suppl 1): S71.
- 95. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Narva AS, Ortiz E. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. Published online December 18, 2013.

- 96. American Diabetes Association, Management of Dyslipidemia in Adults with Diabetes, Diabetes Care 2002; 25 (Suppl 1): S74.
- 97. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 2000; 285:2486-97.
- 98. Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. Published online November 12, 2013.
- 99. Denno KM, Sadler TW. Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology 1994; 49:260-6.
- 100. American College of Obstetricians and Gynecologists. Exercise during pregnancy and the postnatal period. In Home Exercise Programs. Washington, DC, AM College Obstet Gynecol., May 1986.
- Jeffrey E. Harris, "Trends in Smoking-Attributable Mortality," Chapter 3 in: Reducing the Health Consequences of Smoking, 25 Years of Progress: A Report of the Surgeon General (Washington, D.C.: U.S. Department of Health and Human Services, 1989): 17-169.
- 102. Miller RG. Simultaneous Statistical Inference. New York, Springer-Verlag, 1981.
- 103. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley, 1980.
- 104. Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Statistics in Medicine 1992; 11:1871-1879.
- 105. McCullagh P. Regression models for ordinal data. Journal of the Royal Statistical Society, 1980; 42:109-142.
- 106. Lagakos SW, Lim LL, Robins JM. Adjusting for early treatment termination in comparative clinical trials. Statistics in Medicine 1990; 9:1417-1424.
- 107. Agresti A. Categorical Data Analysis. New York, John Wiley, 1990.